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A B S T R A C T
Background
Vitamin C (ascorbic acid) for preventing and treating the common cold has been a subject of controversy for 70 years.
Objectives
To find out whether vitamin C reduces the incidence, the duration or severity of the common cold when used either as a continuous
regular supplementation every day or as a therapy at the onset of cold symptoms.
Search methods
We searched CENTRAL 2012, Issue 11, MEDLINE (1966 to November week 3, 2012), EMBASE (1990 to November 2012),
CINAHL (January 2010 to November 2012), LILACS (January 2010 to November 2012) and Web of Science (January 2010 to
November 2012). We also searched the U.S. National Institutes of Health trials register and WHO ICTRP on 29 November 2012.
Selection criteria
We excluded trials which used less than 0.2 g per day of vitamin C and trials without a placebo comparison. We restricted our review
to placebo-controlled trials.
Data collection and analysis
Two review authors independently extracted data. We assessed ’incidence’ of colds during regular supplementation as the proportion
of participants experiencing one or more colds during the study period. ’Duration’ was the mean number of days of illness of cold
episodes.
Main results
Twenty-nine trial comparisons involving 11,306 participants contributed to the meta-analysis on the risk ratio (RR) of developing a
cold whilst taking vitamin C regularly over the study period. In the general community trials involving 10,708 participants, the pooled
RR was 0.97 (95% confidence interval (CI) 0.94 to 1.00). Five trials involving a total of 598 marathon runners, skiers and soldiers on
subarctic exercises yielded a pooled RR of 0.48 (95% CI 0.35 to 0.64).
Thirty-one comparisons examined the effect of regular vitamin C on common cold duration (9745 episodes). In adults the duration
of colds was reduced by 8% (3% to 12%) and in children by 14% (7% to 21%). In children, 1 to 2 g/day vitamin C shortened colds
by 18%. The severity of colds was also reduced by regular vitamin C administration.
1Vitamin C for preventing and treating the common cold (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Seven comparisons examined the effect of therapeutic vitamin C (3249 episodes). No consistent effect of vitamin C was seen on the
duration or severity of colds in the therapeutic trials.
The majority of included trials were randomised, double-blind trials. The exclusion of trials that were either not randomised or not
double-blind had no effect on the conclusions.
Authors’ conclusions
The failure of vitamin C supplementation to reduce the incidence of colds in the general population indicates that routine vitamin C
supplementation is not justified, yet vitamin C may be useful for people exposed to brief periods of severe physical exercise. Regular
supplementation trials have shown that vitamin C reduces the duration of colds, but this was not replicated in the few therapeutic trials
that have been carried out. Nevertheless, given the consistent effect of vitamin C on the duration and severity of colds in the regular
supplementation studies, and the low cost and safety, it may be worthwhile for common cold patients to test on an individual basis
whether therapeutic vitamin C is beneficial for them. Further therapeutic RCTs are warranted.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C for preventing and treating the common cold
The common cold is a major cause of visits to a doctor in high-income countries and of absenteeism from work and school. There
are over 200 viruses which can cause the common cold symptoms including runny nose, congestion, sneezing, sore throat, cough, and
sometimes headache, fever and red eyes. Symptoms vary from person to person and cold to cold. Since the common cold is usually
caused by one of the respiratory viruses, antibiotics are useless and therefore other potential treatment options are of substantial public
health interest.
Vitamin C has been proposed for treating respiratory infections since it was isolated in the 1930s. It became particularly popular in the
1970s when Nobel laureate Linus Pauling concluded from earlier placebo-controlled trials that vitamin C would prevent and alleviate
the common cold. Over two dozen new trials were undertaken thereafter. Vitamin C has been widely sold and used as a preventive and
therapeutic agent.
This review is restricted to placebo-controlled trials testing 0.2 g/day or more of vitamin C. Regular ingestion of vitamin C had no
effect on common cold incidence in the ordinary population, based on 29 trial comparisons involving 11,306 participants. However,
regular supplementation had a modest but consistent effect in reducing the duration of common cold symptoms, which is based on 31
study comparisons with 9745 common cold episodes. In five trials with 598 participants exposed to short periods of extreme physical
stress (including marathon runners and skiers) vitamin C halved the common cold risk. The published trials have not reported adverse
effects of vitamin C.
Trials of high doses of vitamin C administered therapeutically, starting after the onset of symptoms, showed no consistent effect on the
duration or severity of common cold symptoms. However, only a few therapeutic trials have been carried out and none have examined
children, although the effect of prophylactic vitamin C has been greater in children. One large trial with adults reported benefit from an
8 g therapeutic dose at the onset of symptoms, and two therapeutic trials using five-day supplementation reported benefit. More trials
are necessary to settle the possible role of therapeutic vitamin C, meaning administration immediately after the onset of symptoms.
B A C K G R O U N D
Description of the condition
The term ‘the common cold’ does not denote any precisely de-
fined disease, but this illness is familiar to most people. Typically
symptoms of the common cold consist of some combination of
nasal discharge and obstruction, sore throat, cough, lethargy and
malaise, with or without fever. The common cold is the leading
cause of acute morbidity and of visits to a physician in high-in-
come countries, and a major cause of absenteeism from work and
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school.
The common cold is usually caused by respiratory viruses (rhino,
corona, adeno, parainfluenza, influenza, respiratory syncytial),
which overall have some 200 serotypes (Eccles 2005; Eccles 2009;
Gwaltney 2005; Heikkinen 2003). Thus, the term ‘the common
cold’ does not refer to a single entity but to a group of diseases
caused by numerous unrelated aetiological agents. The most fre-
quent agent causing the common cold is rhinovirus, which is found
in 30% to 50% of sufferers. In a third of participants with cold
symptoms, the aetiology remains undefined even when extensive
virological tests are used. It is not clear to what extent this latter
group is explained by the low sensitivity of the tests, unidentified
viruses, or similar symptoms arising from non-viral aetiology, such
as allergic or mechanical irritation of the airways. Different res-
piratory viruses have different symptom profiles, but the patterns
are not consistent enough to validate aetiological conclusions from
the patients’ symptoms.
Although the great majority of common cold episodes are caused
by the respiratory virus group, the symptom-based definition of
the ‘common cold’ also covers some diseases caused by other viruses
(varicella, measles, rubella, cytomegalo, Epstein-Barr) and some
bacterial infections. For example, since streptococcal pharyngitis
cannot be differentiated from viral pharyngitis on clinical grounds,
it can also be included within the broad definition of the common
cold. Symptoms of illnesses caused by Mycoplasma pneumoniae
(M. pneumoniae) and Chlamydia pneumoniae (C. pneumoniae) may
also be similar to the symptoms caused by the respiratory viruses.
The manifestations of the common cold are so typical that usually
the clinical diagnosis of the common cold can be made reliably
by adult patients themselves. Allergic and vasomotor rhinitis can
sometimes mimic the common cold, but these conditions can
usually be easily differentiated (Heikkinen 2003).
In common cold trials an operational definition of the common
cold is used for logistic reasons; for example, based on the duration
and the set of symptoms to yield an explicitly defined outcome.
However, such limits are biologically arbitrary. There is no exact
minimum duration or combination of symptoms which is mean-
ingful when drawing a conclusion as to whether the symptoms
should be explained by a viral infection, or by allergic or mechan-
ical irritation of nasal airways or throat.
The use of antibiotics for a typical acute common cold episode
is useless since the vast majority of colds are caused by viruses.
Nevertheless, according to some surveys about 50% of common
cold patients in the USA received antibiotics (Gonzales 1997;
Mainous 1996). In this respect, the alternative treatment options
for the common cold are of substantial public health interest.
Description of the intervention
Numerous animal studies with different species have shown that
vitamin C affects resistance to diverse infections by viruses and
bacteria (Hemilä 2006a; Hemilä 1997c). Therefore this vitamin
might play a similar role in infections in human beings. Since the
early 1940s, a number of controlled trials have been carried out to
examine the possible effects of vitamin C on the common cold.
In 1970, the publication of Linus Pauling’s book Vitamin C and
the Common Cold generated huge public interest which persists
today (Pauling 1970a). Pauling had won Nobel Prizes in Chem-
istry (1954) and Peace (1962), and his book had a great influ-
ence. Pauling 1971a also carried out a meta-analysis in which he
combined the P values derived from four placebo-controlled trials
by Fisher’s method and found that there was strong evidence that
vitamin C decreased the ’incidence of colds’ (P = 0.003). In a sec-
ond meta-analysis, Pauling 1971b focused on ’days of illness per
person’ in the best two trials (Cowan 1942; Ritzel 1961) and by
combining the P values by Fisher’s method led him to conclude
that “the null hypothesis of equal effectiveness of ascorbic acid
and placebo [on total morbidity] is rejected at the level P less than
0.001.”
Ritzel 1961 had reported a brief randomised trial of children at
a ski school in the Swiss Alps in which he administered 1 g of
vitamin C daily and found significantly reduced incidence and
duration of colds in children who were administered vitamin C.
Pauling 1971a put much weight on the Ritzel trial. On the basis of
Ritzel’s trial, Pauling proposed that mega-dose supplementation
might profoundly influence both the incidence and severity of the
common cold over all the population. Pauling also presented data
suggesting that human diets might not provide sufficient intake
of vitamin C for best health (Pauling 1970b; Pauling 1976a).
Pauling’s advocacy of vitamin C led to numerous careful trials in
different countries in the following decade, the largest of which
were performed on healthy adult volunteers in Canada (Anderson
1972; Anderson 1974a; Anderson 1975a). The evidence emerging
from all the published trials was confusing (Anderson 1977), but
generally failed to support Pauling’s hope that vitamin C would
be a panacea.
In a meta-analysis, Chalmers 1975 calculated an unweighted av-
erage of the treatment effect in seven placebo-controlled trials and
found that colds in vitamin C groups were 0.11 ± 0.24 (standard
error (SE)) days shorter which is not a statistically or clinically
significant difference. In a qualitative review on vitamin C and
the common cold published in the same year, Dykes 1975 also
concluded that vitamin C had no effect on colds.
However, it has subsequently been pointed out that the influ-
ential reviews by Chalmers 1975 and Dykes 1975 contain seri-
ous errors (Hemilä 1995; Hemilä 1996c; Hemilä 2006a). Hemilä
1995 showed that after extraction of correct data from the trial
reports, correction of errors in calculations, and restriction to trials
in which at least 1 g/day of vitamin C had been used, as Paul-
ing had proposed, Chalmers 1975 would have calculated an eight
times higher estimate of the vitamin C effect: 0.93 ± 0.22 (SE) days
reduction in the duration of colds. Furthermore, both Chalmers
1975 and Dykes 1975 placed considerable weight on the double-
blind, placebo-controlled trial carried out by Karlowski 1975a at
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the National Institutes of Health (NIH), which concluded that a
statistically significant benefit of vitamin C supplementation was
simply explained by the placebo effect. However, it has been shown
that the placebo effect explanation in the Karlowski 1975a paper
was not consistent with their own data (Chalmers 1996; Hemilä
1996a; Hemilä 1996d; Hemilä 2006a; Hemilä 2006c).
Hemilä 1997b claimed that the highly cited reviews of Chalmers
1975 and Dykes 1975 and the trial by Karlowski 1975a quelled
interest in real, but modest effects of vitamin C on the common
cold after the mid-1970s. Hemilä 1997a pooled the results of the
six largest trials using ≥ 1 g/day of vitamin C found no effect on
the common cold incidence (pooled risk ratio (RR) 0.99; 95%
confidence interval (CI) 0.93 to 1.04), which refuted Pauling’s
proposal as to the prophylactic effect of gram-dose vitamin C for
the general population. However, four trials with UK males found
a moderate reduction in common cold incidence with vitamin C
(pooled RR 0.70; 95% CI 0.60 to 0.81), which was explained by
the particularly low dietary vitamin C intake in the UK rather than
high doses of supplements. Also, three trials with participants un-
der heavy acute physical stress found a reduction in the incidence
of colds with vitamin C (pooled RR 0.50; 95% CI 0.35 to 0.69)
(Hemilä 1996b). Thus, it is possible that vitamin C has an effect
on common cold incidence in restricted subpopulations.
Although regular vitamin C supplementation at doses of ≥ 1 g/day
has consistently decreased the duration or alleviated the symptoms
of the common cold, there was substantial heterogeneity in the
results (Hemilä 1994). A further meta-analysis found a trend for
trials with children to show greater benefit than trials with adults,
and another trend for trials with ≥ 2 g/day to show greater benefit
than trials with 1 g/day, suggesting dose-dependency (Hemilä
1999a).
How the intervention might work
Dozens of studies have found that vitamin C may affect, for ex-
ample, phagocytosis and chemotaxis of leucocytes, replication of
viruses, and production of interferon (Hemilä 2006a; Hemilä
1997c; Thomas 1978; Webb 2007). Vitamin C is an efficient
water-soluble antioxidant and the effects on the immune system
can be explained by the protection against oxidative stress gener-
ated during infections (Akaike 2001; Castro 2006; Hemilä 1992).
Phagocytes have a specific transport system by which the oxidised
form of vitamin C (dehydroascorbic acid) is imported into the
cells, where the reduced form of vitamin C is regenerated (Nualart
2003; Wang 1997). If the major role of vitamin C in the immune
system is that of a physiological antioxidant protecting various
host cells against oxidative stress during an infection, it could have
important effects in certain conditions even though the mech-
anisms are apparently non-specific. Furthermore, heavy physical
stress generates oxidative stress (Ji 1999) and the antioxidant role
of vitamin C can thus also explain its effects on respiratory symp-
toms in physically stressed people. Dozens of animal studies found
that vitamin C reduces the incidence and severity of bacterial and
viral infections indicating that the vitamin has physiological effects
on infections, and not just on laboratory measures of the immune
system (Hemilä 2006a).
For brief notes on the history of this Cochrane Review, see
Appendix 1. Links to the publications cited in this section,
for which full-text versions are available, can be found at
www.mv.helsinki.fi/home/hemila/CC/.
Why it is important to do this review
The common cold causes enormous morbidity worldwide and the
search for simple and effective preventive or therapeutic agents
has been elusive. Even if vitamin C might have modest effects
in restricted population groups, that could be important from a
public health point of view.
O B J E C T I V E S
To find out whether vitamin C reduces the incidence, the duration
or severity of the common cold when used either as a continuous
regular supplementation every day or as a therapy at the onset of
cold symptoms.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included placebo-controlled trials. We did not restrict to ran-
domised controlled trials.
Types of participants
Trials of children and adults of either gender and any age were
considered eligible.
Types of interventions
The intervention considered was orally administered vitamin C
of at least 0.2 g daily for a single day or for a period. The limit of
0.2 g/day was selected as a choice of convenience. If a trial with
a lower dose finds a negative result, the negative findings can be
attributed to the low dose. Thus, trials with large doses are more
critical for testing Pauling’s proposal that gram doses of vitamin
C would reduce morbidity due to common cold infections. On
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the other hand, under certain conditions vitamin C doses lower
than 0.2 g/day might have effects (see Discussion: Possible role of
marginal vitamin C deficiency). Thus, our selection criterion for
dose does not mean that all excluded trials are irrelevant to the
question of the effects of vitamin C. All trials that used a vitamin
C dose lower than 0.2 g/day are listed and briefly described in the
Characteristics of excluded studies table.
In a few instances the placebo included a low dose of vitamin C;
Carr 1981a used 70 mg/day and a few others used 50 mg/day or
less. This was done to ensure that participants were not ’vitamin
C deficient’, recognising that dietary intake of vitamin C is highly
variable. Thus, the goal of these investigators was to test the effects
of large doses for properly nourished participants.
We may include studies in which vitamin C has a co-intervention
if the control group has only the co-intervention so that the only
difference is vitamin C administration.
Types of outcome measures
Primary outcomes
1. ’Incidence’ of colds during regular supplementation was
assessed as the proportion of participants experiencing one or
more colds during the study period.
2. ’Duration’ was the mean number of days of illness of cold
episodes.
Secondary outcomes
1. ’Severity’ of these episodes was assessed in two ways: a) days
confined indoors, or off work or off school per episode and b)
symptom severity scores.
2. ’Evidence of possible medication side effects’ was available
from seven large regular supplementation studies, with the
number of participants reporting possible medication side effects
in the intervention and control groups.
Search methods for identification of studies
Electronic searches
For this 2012 update we searched the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL) 2012, Issue 11, part of
The Cochrane Library, thecochranelibrary (accessed 29 May 2012),
which contains the Acute Respiratory Infections Group’s Spe-
cialised Register, MEDLINE (January 2010 to November week 3,
2012), Embase.com (January 2010 to November 2012), CINAHL
(January 2010 to November 2012), LILACS (January 2010 to
November 2012) and Web of Science (January 2010 to November
2012). See Appendix 1 for details of previous searches.
We used the following search strategy to search CENTRAL and
MEDLINE. The search strategy was adapted to search EMBASE
(Appendix 2), CINAHL (Appendix 3), LILACS (Appendix 4) and








7 ((viral or virus*) adj2 rhinit*).tw.
8 or/1-7
9 exp Ascorbic Acid/
10 ascorb*.tw,nm.
11 (vitamin* adj5 c).tw.
12 or/9-11
13 8 and 12
There were no language or publication type restrictions in the
literature searches.
Searching other resources
The review authors screened the reference lists incorporated in two
systematic reviews of the literature published by Briggs 1984 and
Kleijnen 1989 (for the search strategy of the latter, see Kleijnen
1992) and the references in all identified studies. Furthermore, one
of the review authors (HH) has a research involvement spanning
three decades in this topic and has assembled a personal reference
list of papers published in the grey literature or listed in indexing
services that preceded electronic searching.
We also searched the U.S. National Institutes of Health trials reg-
ister www.clinicaltrials.gov and the WHO ICTRP www.who.int/
ictrp on 29 May 2012 (see Appendix 6 for search details).
Data collection and analysis
Selection of studies
For the 2004 version of this review, HH and Bob Douglas (BD)
searched the literature and independently assessed the titles and ab-
stracts to identify potentially relevant articles (Appendix 1). They
obtained and scrutinised full versions of all potentially eligible ar-
ticles. When they disagreed on the relevance of an article, they
discussed it until they reached a consensus. For the 2007 and 2009
updates, the first review author (HH) searched the literature and
assessed the titles and abstracts to identify potentially relevant arti-
cles. For the 2012 update, two review authors (HH, EC) searched
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the literature and assessed titles and abstracts to identify poten-
tially relevant articles.
Data extraction and management
For the 2004 version of this review, two review authors (HH,
BD) independently extracted pertinent data from the articles se-
lected and entered data into the Review Manager program (see
Appendix 1) (Douglas 2004; RevMan 2011). They sought con-
sensus when they differed in the interpretation of study findings.
Only one new trial satisfying the selection criteria (Constantini
2011a; Constantini 2011b) has been published since the preced-
ing version of this review (Hemilä 2010) and it was included in
this 2012 update.
Assessment of risk of bias in included studies
Most of the included trials were double-blind. Double-blind
means that the participant and others directly involved in treat-
ment do not know to which treatment group the participant has
been allocated, i.e. there must be allocation concealment. Double-
blind also means that there must be blinding of participants and
personnel. Finally, since the outcomes were recorded by person-
nel or the participant, double-blinding also implies that there is
blinding of outcome assessment.
Studies are classified as randomised on the basis of the study re-
ports, but only a few studies described the actual method of ran-
domisation.
Chalmers 1975 proposed that the benefits of vitamin C supple-
mentation on the common cold might be caused by “the result of
the power of suggestion.” His proposal was based on the Karlowski
1975a trial, in which placebo consisted of lactose which is sweet
and differs by taste from ascorbic acid which was used in the vi-
tamin C capsules. Therefore, we collected data on the reported
indistinguishability of vitamin C and placebo preparations.
When the methodological description was unambiguous, one re-
view author (HH) entered the methodological description to the
’Risk of bias’ tables in Characteristics of included studies. When
the description of methods was ambiguous, HH discussed the is-
sue with the co-author (EC) to reach a consensus. The overall risk
of bias is summarised in Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Measures of treatment effect
For the community trials, we selected two primary outcomes
and one secondary outcome to compare vitamin C with placebo
groups, resulting in five tables.
Analysis 1.1: the measure of the treatment effect is the risk ratio
(RR) of ’incidence’ of colds in vitamin C and placebo groups.
Incidence is defined as the proportion of participants with at least
one cold during the study.
Analysis 2.1 and Analysis 4.1: the measure of treatment effect is
the mean difference (MD) in common cold ’duration’. Since dura-
tion of cold episodes varied appreciably across trials, we standard-
ised the mean values and standard deviations (SD) in each group
against the mean of the respective placebo group. In this way, the
placebo group of each trial gets a value of 100%, and therefore the
difference between the vitamin C and placebo group is the effect
of vitamin C in percentages.
Analysis 3.1 and Analysis 5.1: there are two measures of effect on
’severity’: a) the difference in the mean number of days that the
patient was absent from work or school or confined to bed; and b)
the difference in the mean symptom severity score derived from
patient kept records.
In analysing dichotomous data with only a few cases in the trial
groups, the mid-P value is the most appropriate method to cal-
culate the P values for the differences in the treatment groups
(Hemilä 2006a) and was used when comparing groups with small
numbers of cases. Two-tailed P values are used in this review.
Unit of analysis issues
In four of the trials (Anderson 1974a; Anderson 1975a; Audera
2001a; Karlowski 1975a) more than one vitamin C group was
compared with a single placebo group. Where multiple active arms
were analysed in the same meta-analysis, the vitamin C arms were
combined as one entry which appears in the figures, identified as
the lowest lettered trial that the entry contained.
Miller 1977a and Carr 1981a studied twins and the comparison
is paired. The SD values used in this meta-analysis are calculated
from the SE and P values, respectively, of reported paired tests, so
the two trials get proper weight in pooling.
Dealing with missing data
Some trials presented the mean duration or severity of colds, but
not the respective SD. In some trials the P value for the difference
of interest was reported and the SD was calculated from it. In
the Anderson 1972, Anderson 1974a and Anderson 1975a trials,
Fieller’s theorem was used to estimate the SD for individual com-
mon cold episodes from the SD values presented in papers that
were based on a per person experience. In the other trials with
missing SD, we estimated SD as identical with the mean of the
treatment group. This is based on our analysis that for trials report-
ing the SD, the ratio of SD to mean is on average 0.7 so that our
ratio of 1.0 used in the SD imputation is somewhat conservative.
The consequence of this is that we are putting slightly reduced
weight in our estimates of effect on these trials with missing SD
values, compared to the average.
Assessment of heterogeneity
We assessed heterogeneity using the Chi2 test and the I2 statistic
(Higgins 2003; Higgins 2011). The Chi2 test is known to be poor
at detecting true heterogeneity among studies. While a statistically
significant result indicates heterogeneity, a non-significant result
is not evidence of no heterogeneity. The I2 statistic examines the
percentage of total variation across studies that is due to hetero-
geneity rather than chance. A value of about 50% for I2 indicates
a moderate level of heterogeneity.
Data synthesis
We used the Review Manager (RevMan 2011) software to pool the
results of the three outcomes of the included trials. A pooled fixed-
effect RR of the probability of experiencing at least one cold while
taking vitamin C was computed for ‘incidence’. We computed a
pooled fixed-effect MD in common cold ‘duration’ to derive an
estimate of the percentage of days of illness by which vitamin C
reduced the average common cold.
We considered separately two different approaches to the assess-
ment of severity in the meta-analysis by treating the two measures
of severity as separate subgroups. We computed a standardised
mean difference (SMD) for the two subgroups and for all the tri-
als for which severity data were available. The SMD calculation
method leads to quantitative results but the estimates do not have
any relevant clinical interpretation. Rather the primary statistical
result of the SMD method is the P value for the combined set.
Subgroup analysis and investigation of heterogeneity
We considered three factors as possible explanations for hetero-
geneity observed across the results of these trials. These were vita-
min C dosage, age of the participants (children and adults), and
the presence or absence of heavy, short-term physical stress.
Sensitivity analysis
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We undertook sensitivity analyses in Analysis 1.1 and Analysis 2.1
to test the robustness of our conclusions regarding the method-
ological quality of the trials, in which we excluded all studies which
were not randomised and double-blind.
In seven trials in Analysis 2.1 (’Duration of colds in regular sup-
plementation trials’) we imputed the SD values assuming that SD
is equal to the mean of the group (Briggs 1984; Coulehan 1974a;
Coulehan 1974b; Coulehan 1976; Peters 1996a; Peters 1996b; Pitt
1979). When we excluded these seven trials in a sensitivity anal-
ysis of Analysis 2.1, the pooled results indicated a slightly greater
effect of vitamin C: for adults 8.6% (4% to 13%); for children
14.6% (7% to 22%). Thus, inclusion of the trials with imputed
SD values does not lead to an increase in the estimate of benefit,
but leads to a slight reduction in the calculated benefit.
We also tested whether the exclusion of the Anderson 1974a trial
might affect the estimates of Analysis 1.1 and Analysis 2.1. That
trial had two placebo groups and we selected for our comparisons
the placebo group #4 which was close to the vitamin C groups on
the basis of baseline data (see Hemilä 2006a and Results section
4). Exclusion of the Anderson 1974a trial had minimal effects on
the pooled estimates (not shown).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The 2012 MEDLINE (Ovid) search identified 17 results, EM-
BASE 58, CENTRAL 6, CINAHL 20, LILACS 0, Web of Sci-
ence 13, Clinicaltrials.gov 3 and WHO Trials Register (ICTRP)
1 search results. With duplicates removed there were 90 search re-
sults. One new trial satisfying our inclusion criteria was identified
in the 2012 search (Constantini 2011a) and two new trials were
added to the excluded trials list (Maggini 2012; Schmidt 2011).
Included studies
Sixty-three separate comparisons of vitamin C against placebo,
reported in 44 publications, met our selection criteria. Eleven of
these publications presented the results of two to six different study
comparisons. Included in the selected papers are the four trials
identified originally by Pauling 1971a to justify his proposals for
mega-dose regular supplementation and therapy (Cowan 1942;
Franz 1956; Ritzel 1961; Wilson 1969). We have used the Wilson
1973a final report of his boarding school trials rather than the
preliminary communication which Pauling 1971a had available
to him.
In Anderson 1974a, Anderson 1975a, Audera 2001a and
Karlowski 1975a more than one active arm is compared with a
single placebo arm. This explains why the total number of partic-
ipants is less in the placebo groups than in the vitamin C groups.
The 63 included trials which have contributed data to this review
fall into four groups.
1. Forty-three community regular supplementation trial arms
which evaluated the effects of regular daily supplementation with
vitamin C (i.e. vitamin C each day over the study irrespective of
the presence of colds) on reducing the incidence or duration or
severity of naturally occurring colds.
2. Ten community therapeutic trial arms that evaluated the
therapeutic effects of high-dosage vitamin C after natural
common cold symptoms had commenced.
3. Seven community trials did not report data suitable for our
meta-analysis and these trials are presented qualitatively.
4. Three laboratory trials (Dick 1990; Schwartz 1973; Walker
1967) in which volunteers were intentionally exposed to known
viruses after vitamin C or placebo administration. As they are
qualitatively different from the community-based trials on
natural common cold infections, they are not included in the
meta-analyses but are presented qualitatively.
Brief details of the circumstances, dosage and quality assessment
of the trials are available in the Characteristics of included studies
table. Links to the trial reports and translations can be found at
www.mv.helsinki.fi/home/hemila/CC/.
Excluded studies
We excluded 25 studies. The major reasons for exclusion were the
lack of placebo control (12 trials) and vitamin C dose < 0.2 g/day
(seven trials). For details, please see the Characteristics of excluded
studies table.
Risk of bias in included studies
Allocation
Most of the identified trials were randomised controlled trials
(RCTs) (Figure 1). Most of the studies also had allocation con-
cealment (Figure 1).
Blinding
Most of the identified trials blinded participants and personnel
and the outcome was assessed by either of the two so that the
outcome assessment was also blinded (Figure 1).
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Incomplete outcome data
In many trials there were no drop-outs, and in those trials in which
there were, the number of drop-outs was not substantially different
between the study groups.
Selective reporting
When there are one or a few trials with a positive finding on a
poorly justified outcome, the possibility of publication bias is an
important concern. In our review we have two large groups of tri-
als with the same well-justified primary outcomes: incidence and
duration of colds (Analysis 1.1 and Analysis 2.1). We do not see
any basis to speculate that the consistency in these two outcomes
could be explained by selective reporting. There is no unambigu-
ous definition for severity which we classify as a secondary out-
come, and there might be more problems with selective reporting
on that outcome (Analysis 3.1). However, severity has a lower pri-
ority in our review and the findings are consistent with the effect
on duration (Analysis 2.1).
Other potential sources of bias
The great majority of the trials reported that vitamin C tablets
(usually ascorbic acid) and placebo tablets (usually citric acid) were
indistinguishable (Figure 1 and Characteristics of included studies
table). Thus there is no basis to assume that difference in taste or
appearance between the tablets could have generated substantial
bias in the trials.
Effects of interventions
1. Community regular supplementation trials:
incidence of colds
Analysis 1.1 (Figure 2) presents the meta-analysis of the risk ratio
of at least one cold developing for a participant while on regular
vitamin C supplementation. Regular supplementation means that
vitamin C was administered each day over the study period. The
entry in the meta-analysis for Anderson 1974a represents four
separate trial arms (Anderson 1974a; Anderson 1974b; Anderson
1974c; Anderson 1974d) in which different vitamin C dosages
ranging from 0.25 to 2 g/day were compared with one placebo
group. Thus the 29 entries in Figure 2 represent 32 vitamin C
arms in trials.
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Figure 2. Forest plot of comparison: 1 Incidence of colds while taking ≥ 0.2 g/day vitamin C regularly,
outcome: 1.1 Proportion of participants developing ≥ 1 cold episodes during the trial
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The 29 entries represent 11,306 participants, of whom 6105 used
vitamin C for periods ranging from two weeks to five years. The
pooled risk ratio (RR) for all trials was 0.95 (95% confidence in-
terval (CI) 0.92 to 0.98). Although the overall difference between
vitamin C and placebo participants is statistically highly signifi-
cant (P = 0.001), indicating a biological effect of vitamin C, the
narrow CI precludes any clinically relevant effect over wide pop-
ulation groups.
Heterogeneity of results
Among all the studies included in Analysis 1.1 there is substantial
heterogeneity, as indicated by the Chi2 test (P = 0.02) and the
rather high I2 statistic (38%). Heterogeneity refutes the notion
that vitamin C is universally equivalent to placebo.
Five of the 29 comparisons recorded statistically significant (P <
0.05) protection favouring the vitamin C group: Peters 1996a (RR
0.39), Peters 1993a (RR 0.50), Ritzel 1961 (RR 0.55), Charleston
1972 (RR 0.77) and Anderson 1972 (RR 0.91). Four other trials
recorded a non-significant RR < 0.80 (Moolla 1996a; Moolla
1996b; Peters 1996b; Sabiston 1974). None of the 29 comparisons
significantly favoured the placebo.
Of the eight relatively small trials with RR < 0.8, three were with
marathon runners (Moolla 1996a; Peters 1993a; Peters 1996a),
two with sedentary controls for marathon runners (Moolla 1996b;
Peters 1996b), one with students in a skiing school in the Swiss
Alps (Ritzel 1961), one with Canadian army troops on subarctic
operations (Sabiston 1974), and one with staff and students at
Glasgow University, UK (Charleston 1972).
The bottom of Analysis 1.1 shows a subgroup of five studies which
involved marathon runners, skiers and Canadian soldiers in a sub-
arctic exercise. Division of the 29 trials to the two subgroups re-
sulted in two distinct groups of trials which were significantly dif-
ferent from each other in their pooled estimates of effect. Fur-
thermore, the two subgroups were homogeneous within the two
pools, as indicated by the high P values in the Chi2 test, and the
zero values for the I2 statistic.
Subgroups: general community trials and heavy acute
physical stress trials
Based on 24 entries with 10,708 participants from the general
community who had no heavy short-term physical stress, the nar-
row CI, which is located close to the zero effect, refutes the pos-
sibility that regular vitamin C supplementation could reduce the
average incidence of colds in the general community: RR 0.97
(95% CI 0.94 to 1.00) (Analysis 1.1; Figure 2).
When the general community meta-analysis was restricted to 17
entries with vitamin C dose ≥ 1 g/day, the prophylactic benefit of
vitamin C supplementation was also refuted (RR 0.98; 95% CI
0.95 to 1.01; based on 6661 participants).
In the Karlowski 1975a trial, the dose of vitamin C was the highest,
3 g/day. This study is not included in Analysis 1.1 because the
number of participants who caught a cold during the trial was not
reported; instead the total number of cold episodes per group was
reported. Nevertheless, 3 g/day vitamin C had no effect on the
number of common cold episodes, with RR 0.93 (95% CI 0.73
to 1.20) (Hemilä 1997a).
In five trials with participants undergoing heavy acute physical
activity in the subgroup at the bottom of Analysis 1.1, vitamin
C halved the incidence of colds: RR 0.48 (95% CI 0.35 to 0.64)
(Figure 2, Analysis 1.1.2). All of these five studies were randomised
and double-blind. In three of these studies, the vitamin C dose
was less than 1 g/day so that the benefit in this subgroup cannot
explained by particularly high vitamin C doses, but by the extraor-
dinary conditions of the participants.
Two trials had participants exposed to long-term physical stress.
Pitt 1979 examined 674 US marine recruits for two months and
Constantini 2011a studied 39 competitive young swimmers for
three months. Neither of these trials found effect of vitamin C on
common cold incidence.
To test the effect of study quality on the findings in Analysis 1.1, we
undertook a sensitivity analysis in which we removed five trials that
were either not randomised or not double-blind from the general
community meta-analyses and this had no effect on the estimate
(RR 0.98; 95% CI 0.94 to 1.01). All trials with participants under
heavy acute physical stress were randomised and double-blind.
Thus, the effect of study quality as assessed by randomisation and
double-blinding did not change the estimates of the two subgroups
of Figure 2.
2. Community regular supplementation trials:
duration of colds
Analysis 2.1 (Figure 3) presents the effect of vitamin C on the du-
ration of colds which occurred while participants were taking vi-
tamin C regularly, each day over the study. These trials are divided
into two subgroups: adults and children. The division into child
and adult trials was carried out for two reasons: a) children have a
substantially higher incidence of colds reflecting differences in the
immune system maturity, and b) children are on average smaller
so that a fixed dose corresponds to a greater dose per weight.
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Figure 3. Forest plot of comparison: 2 Duration of the colds occurring when on regular ≥ 0.2 g/day vitamin
C, outcome: 2.1 Duration of common cold symptoms (placebo group duration 100%)
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For adults there were 17 entries representing 21 trial arms (four
separate trial arms in Anderson 1974a and two in Karlowski
1975a) and 7215 episodes of illness, and for children there were
14 trial comparisons including 2530 episodes of illness.
A consistent benefit was seen in the duration of colds. For chil-
dren, the pooled effect was a 14.2% (7.3% to 21%) reduction
in common cold duration, and for adults the pooled effect was a
7.7% (3.7% to 12%) reduction in cold duration. The Chi2 test for
trial heterogeneity was not significant in either of the subgroups.
In five of the 31 comparisons (Carr 1981b; Constantini 2011a;
Charleston 1972; Ludvigsson 1977a; Ritzel 1961) the effect of
vitamin C was statistically significant within the trial. In the
Constantini 2011a trial, common cold duration was significantly
shorter in male swimmers, but not in female swimmers, there be-
ing a statistically significant interaction between vitamin C effect
and sex.
Five comparisons (Carr 1981a; Constantini 2011b; Peters 1993a;
Peters 1996b; Wilson 1973b) recorded a point estimate favouring
the placebo. Wilson 1973b used only 0.2 g/day vitamin C, which is
the smallest dose in the analysis. Carr 1981a examined twins living
together, whereas the Carr 1981b trial examined twins living apart;
it is possible that the substantially divergent result in these twin
groups is related to the living conditions - those living together
might have exchanged or confused their tablets. The Peters 1996b
trial was very small and the CI is very wide.
The great majority of the trials in Analysis 2.1 used 1 g/day of vi-
tamin C and therefore a systematic examination of possible dose-
dependency across the trials was not feasible. In the child sub-
group, we used sensitivity analysis to test the possibility that low-
dose vitamin C trials might dilute the pooled estimate. When we
removed the trials using < 1 g/day of vitamin C (Miller 1977b;
Miller 1977c; Wilson 1973a; Wilson 1973b), the pooled estimate
of benefit was increased to a 18.1% (9% to 27%) reduction in the
duration of colds in children suggesting that the 14.2% estimate
for all studies of children may be biased downwards because low-
dose trials are included. In the adult subgroup, the estimate of ef-
fect was essentially unchanged, 8.0% (3.8% to 12%), when the < 1
g/day vitamin C trials were removed (Peters 1993a; Peters 1993b;
Peters 1996a; Peters 1996b); these are small trials with doses of
0.5 to 0.6 g/day.
In sensitivity analyses, we removed the studies which were not ran-
domised and double-blind. Exclusion of two trials from the adult
subgroup had no material effect on the estimated benefit of 7%
(3% to 11%), and exclusion of two trials from the child subgroup
similarly had no substantial effect on the estimated benefit of 14%
(7% to 21%). Thus, excluding four trials with lower quality had
no effect on the conclusions of Figure 3.
In summary, this meta-analysis of the duration of colds occurring
while participants were on regular vitamin C supplementation
demonstrated a statistically highly significant, but modest, benefit
to the vitamin C supplemented participants which was greater in
children than in adults.
3. Community regular supplementation trials:
severity of colds
Analysis 3.1 presents the effect of vitamin C on the severity of
common cold episodes occurring during regular vitamin C sup-
plementation. Two measures of the severity of the common cold
were available.
Subgroup 1 in Analysis 3.1 consists of seven entries of 10 vitamin
C study arms in which severity was measured by ’days confined
to home’ or ’days off work or school’. This included 5066 com-
mon cold episodes in adults and children. The large-scale trials
by Anderson 1972 and Ludvigsson 1977b reported statistically
significant reductions in ’days confined to house per episode’ with
vitamin C supplementation. Subgroup 1 found a quantitatively
modest, but statistically highly significant reduction in common
cold severity. This subgroup exhibited significant heterogeneity
between the studies as measured by the Chi2 test and I2 statistic.
Subgroup 2 in Analysis 3.1 presents the results of symptom sever-
ity scores in nine trials with 2143 episodes. The large-scale trial
by Pitt 1979 found a statistically significant, but small, 5% reduc-
tion in the severity score. There is a statistically highly significant
reduction in common cold severity also in subgroup 2. There is
no heterogeneity in this subgroup.
The measures of ’severity’ that have been used in the included
trials are variable. We calculated the standardised mean difference
(SMD) which normalises the difference between the vitamin C
and placebo groups to the units of standard deviations. Therefore
the pooled results of Analysis 3.1 are not practically useful, rather
the significance level is of main importance in this analysis; P =
0.0004 for the studies that assessed days confined to home or off
work or school, and P = 0.002 for studies which used severity
scores, and P < 0.00001 when the two subgroups were combined.
Although the benefit with respect to days confined to home or
off work or off school is statistically significant, it is modest in
absolute terms.
4. Community therapeutic studies: duration of colds
when treatment commenced after common cold
symptoms began
Analysis 4.1 presents the findings of therapeutic trials, which
means that vitamin C administration was started after the cold
symptoms occurred. This meta-analysis contains seven entries that
incorporate data from 10 different trial arms involving 3249 cold
episodes where participants initiated supplementation at the onset
of cold symptoms. Audera 2001a, Anderson 1974e and Anderson
1975a contain two vitamin C arms.
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The pooled result for these therapeutic trials did not exhibit a dif-
ference of vitamin C from placebo in the variety of therapeutic
protocols that were used. The large trial by Anderson 1974e found
a statistically significant but modest benefit but this was counter-
balanced by the negative results in the other trials.
The Anderson 1974e entry combines two arms with different
dosages. Anderson 1974e administered 4 g/day and Anderson
1974f administered 8 g/day on the first day of illness only. The
mean duration of illness episodes for those in the 4 g/day arm
was 3.17 days, while that for 8 g/day arm was 2.86 days com-
pared with the duration in the placebo group #4 of 3.52 days.
However, this trial was bedeviled by the fact that the investigators
originally intended to compare results with two separate placebo
groups. One of the two placebo groups (#6) had statistically sig-
nificant baseline differences when compared with the six vitamin
C groups. The comparisons presented here are with the placebo
group #4 that was close to the vitamin C groups with respect to the
baseline data (see Hemilä 2006a). If comparisons had been made
with the placebo group #6 or a combination of the two placebo
groups as the investigators had originally intended, the benefits
would have been minimised as the mean episode duration for the
placebo group #4 was 3.52 days, and for placebo group #6 was
2.83 days. Nevertheless, notwithstanding the placebo group prob-
lem, the proportion of ’short colds’, that lasted for only a single
day was significantly larger in the 8 g/day group (46%; 222 out
of 483) compared with the 4 g/day group (39%; 164 out of 417)
(P = 0.046), consistent with a greater benefit with the higher dose
compared with the lower dose.
Tyrrell 1977, Elwood 1977 and Audera 2001a failed to show an
effect on duration. Tyrrell evaluated males and females separately
using a dosage of 4 g/day for the first 2.5 days of illness (total 10
g), Elwood evaluated males and females separately using a dosage
of 3 g/day for the first 3.3 days of illness (total 10 g), and Audera
evaluated 1 and 3 g/day over the first 3 days (total 3 g and 9 g).
In summary, the therapeutic trials do not provide consistent evi-
dence that the duration of colds could be reduced with the proto-
cols that have been tested in the vitamin C trials. The benefit from
the use of an 8 g single dose immediately after the onset of cold
symptoms is interesting but indicates the need for further research
rather than implying practical conclusions.
5. Community therapeutic studies: severity of cold
episodes when treatment commenced after common
cold symptoms began
Analysis 5.1 has four entries which represent seven trial arms
that included 2708 separate common cold episodes for which
cold severity was assessed. Audera 2001a, Anderson 1974e and
Anderson 1975a contain two vitamin C arms.
As with the regular supplementation studies, we separated the mea-
sures of severity into two subgroups: a) days confined to home, off
work or school, and b) symptom severity scores, and we analysed
these subgroups separately and together.
In subgroup 1, the only comparison which found a significant
benefit to those taking vitamin C was that for Anderson 1975a.
In that study, participants took 1.5 g/day for the first day of the
common cold and 1 g/day for the following four days (total 5.5 g).
Anderson 1974e and Tyrrell 1977 found no meaningful difference
between vitamin C and placebo. The pooled effect for subgroup
1 shows a marginally significant benefit of vitamin C.
The only trial in subgroup 2, Audera 2001a, found no difference
between vitamin C and placebo.
6. Community trials with no data suitable for our
meta-analyses
Table 1 shows the findings in seven trials which did not report
suitable data for our meta-analysis. Two of them were regular sup-
plementation trials and five were therapeutic trials. All these are
placebo-controlled trials which used ≥ 0.2 g/day of vitamin C.
The main findings of these trials are described in Table 1.
In two therapeutic trials the authors claimed to be able to identify
the vitamin C and placebo participants from the clinical progress
of the patients (Asfora 1977; Regnier 1968). One therapeutic trial
found a marginally significant effect on the duration of “nose
colds” (Brown 1945), and two therapeutic trials reported no dif-
ference between vitamin C and placebo (Abbott 1968; Tebrock
1956).
In a regular supplementation trial, Elliot 1973 found a significant
effect of vitamin C on the morbidity for sore throats and produc-
tive coughs, but the study was carried out in a Polaris submarine
so that the conditions were special. Scheunert 1949 reported less
respiratory morbidity in persons administered higher doses of vi-
tamin C compared with lower doses, but the study is poorly re-
ported and methodologically unsatisfactory.
7. Laboratory trials with artificially infected
volunteers
Table 2 presents three laboratory trials which were volunteer trans-
mission studies.
Walker 1967 and Schwartz 1973 instilled virus into the noses of
volunteers who had been pre-treated with vitamin C or placebo.
Dick 1990 used a more natural mechanism for the transmission of
a rhinovirus: their experimental volunteers were housed for a week
and worked closely with other volunteers who had been previously
infected by nasal instillation of rhinovirus.
Dick 1990 found that fewer vitamin C treated volunteers became
infected and the cumulative symptom severity score and mucus
weights were significantly less (P = 0.03), but virus shedding was
similar in both groups. Schwartz 1973 found reduced common
cold severity in the vitamin C group (P < 0.02 at day 4), but no
effect on symptom duration, whereas Walker 1967 did not observe
any benefit to those who took vitamin C.
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8. Adverse effects from high-dose vitamin C intake
Seven large trials recorded data on symptoms which participants
attributed to the medication they were using.
Over the trials, data were recorded for a total of 2490 recipients
who had used ≥ 1 g/day of vitamin C compared with 2066 who
took a placebo. Altogether 5.8% of the vitamin C recipients re-
ported adverse symptoms which they attributed to the medication
compared with 6.0% of those who were taking placebo (data not
shown). No serious symptoms were reported.
D I S C U S S I O N
Despite the variation in methodology and the substantial hetero-
geneity in results from this large number of trial results carried
out over a 70-year period, certain rather strong conclusions can be
drawn.
Common cold incidence
Trials within the general community
An earlier meta-analysis pooled the results of the six largest trials in
which ≥ 1 g/day of vitamin C had been administered regularly over
the study period and found no effect of vitamin C on the incidence
of colds with a narrow confidence interval (CI) (risk ratio (RR)
0.99; 95% CI 0.93 to 1.04) (Hemilä 1997a). This earlier meta-
analysis pooled the number of common cold episodes occurring
during the trial, whereas this Cochrane meta-analysis used the
number of participants catching at least one cold as the measure
of common cold incidence. Nevertheless, this second outcome
definition led to the same conclusion for the general community
trials.
When the subgroup of marathon runners, skiers and soldiers on
subarctic operations was excluded in this review (see below), there
was strong evidence that vitamin C supplementation has no effect
on the number of people who catch the common cold (RR 0.97;
95% CI 0.94 to 1.00). This estimate was based on trials in which
the vitamin C dose was ≥ 0.2 g/day. However, the negative finding
is not explained by the inclusion of a few trials in which vitamin C
dose was low. When restricting to trials in which the vitamin C dose
was ≥ 1 g/day, the estimate was essentially the same. Finally, the
general community trial with the largest dose, 3 g/day of vitamin
C, found no difference in the common cold incidence between the
vitamin C and placebo groups (Hemilä 1997a; Karlowski 1975a).
Trials with people under heavy acute physical stress
A previous meta-analysis identified three trials with participants
under severe acute physical stress, and the pooling of results found
that vitamin C supplementation halved the incidence of colds in
this group (Hemilä 1996b). Two later trials with marathon run-
ners (Moolla 1996a; Peters 1996a) are included in our Cochrane
Review and they have not changed the pooled estimate of effect:
RR 0.48; 95% CI 0.35 to 0.64. All five trials in this group involved
a brief exposure to high physical stress with or without cold stress.
The doses of vitamin C were not particularly high, being between
0.25 and 1.0 g/day. Thus, the benefit in this subgroup cannot be
explained by high vitamin C doses. Similar and higher doses in
the general community have not affected the incidence of colds
(see above).
Furthermore, in the general community the acute respiratory
symptoms usually have a viral cause, but it is not obvious that sim-
ilar symptoms occurring after heavy exercise are caused by a viral
infection because they can also result from exercise-induced bron-
choconstriction (EIB) symptoms caused by an injury to the air-
ways because of exceptional ventilatory exertion (Anderson 2008).
In three trials, vitamin C supplementation reduced the decrease in
pulmonary function associated with EIB (Hemilä 2009c). Thus
the common cold studies of physically stressed people might have
been measuring, at least in part, the effects of vitamin C on EIB
instead of viral infections. Nevertheless, although the aetiology of
symptoms is not clear in the physically stressed subgroup, the ben-
eficial effect of vitamin C on acute respiratory symptoms in this
subgroup is firm.
Two trials with two to three months physical stress on the partic-
ipants found no effect of vitamin C on common cold incidence
(Constantini 2011a; Pitt 1979). It is thus possible that vitamin C
has effects on short-term exposure to physical stress, but not on
long-term physical stress.
Possible role of marginal vitamin C deficiency
Hemilä 1997a has suggested that some of the early benefits of
vitamin C supplementation might be a explained by low dietary
vitamin C intakes in the UK when the studies were carried out
(Baird 1979; Bartley 1953; Glazebrook 1942). These trials were
ruled ineligible for this review because the doses were lower than
0.2 g/day. Low dietary vitamin C intake might also explain the
significant reduction in cold incidence in the Charleston 1972 UK
trial which is included in Analysis 1.1.
Four UK trials also found a reduction in the incidence of recurrent
colds during the study period in males (pooled RR 0.54; 95% CI
0.40 to 0.74) but not in females (Hemilä 1997a). Nevertheless,
a recent UK trial found a reduction in recurrent colds in a nine-
week trial in both sexes (RR 0.13; 95% CI 0.03 to 0.53) (Van
Straten 2002) (see Hemilä 2006a). The most impressive trial in
this UK group is the Baird 1979 study, which was a randomised,
double-blind, placebo-controlled trial, but was excluded from our
Cochrane Review because the vitamin C dose was only 0.08 g/day.
Thus, methodological weaknesses cannot explain the reduction
in common cold incidence in males and the highly significant
modification of vitamin C effect by sex (Hemilä 1997a; Hemilä
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2008). Significant sex differences in the effect of vitamin C were
also found in a recent trial with competitive swimmers so that
vitamin C was effective for males but not for females (Constantini
2011a).
The large trial by Anderson 1972 found a statistically significant
but small reduction in common cold incidence (RR 0.91; 95%
CI 0.85 to 0.98). This trial was conducted during the winter in
Toronto, Canada, and participants were selected on the basis of
having had problems with colds during previous winters. A cold
Canadian winter might be a partial explanation for the benefit
if cold along with physical stress makes a prophylactic benefit
for vitamin C more likely. Furthermore, as regards the possible
interaction between vitamin C supplementation and the level of
dietary vitamin C intake, the Anderson 1972 trial is important
as it found that vitamin C supplementation reduced the ’total
days indoors’ by 48% among participants in the vitamin C group
who consumed < 3 oz of fruit juice (common dietary source of
vitamin C), whereas the reduction was only 22% among those
who consumed more juice. A similar modifying effect with fruit
juice was found in the therapeutic trial by Anderson 1975a (see
Hemilä 2006a).
Common cold duration and severity: regular
supplementation trials
Both in adults and in children, regular vitamin C supplementa-
tion resulted in a statistically highly significant reduction in the
duration of common cold episodes that occurred during the pro-
phylactic supplementation period. For adults the estimate of vi-
tamin C effect was 8% and for children it was 14%. However,
when restricting to children trials with ≥ 1 g/day of vitamin C,
the pooled estimate was an 18% decrease in the duration of colds.
Although the above findings point to a definite physiological effect
from regular vitamin C supplementation on common cold dura-
tion, the practical significance of these findings is not convincing.
It does not seem reasonable to ingest vitamin C regularly through-
out the year if the anticipated benefit is to slightly shorten the
duration of colds which occur for adults a few times per year and
for children half a dozen times per year. The above estimates are
not trivial, but instead of regular supplementation, it would seem
much more fruitful to consider the possible benefits of therapeutic
supplementation and carry out trials to test whether an equivalent
benefit might be achieved in children through appropriate thera-
peutic supplementation.
In light of the consistent effect of vitamin C on the duration of
colds, an obvious question is whether there might be dose depen-
dency, as suggested by a previous meta-analysis (Hemilä 1999a).
Across the available trials, there is more evidence for the difference
between children and adults than on the variation of vitamin C
effect by the dose used. Few trials have used more than 1 g/day of
vitamin C in the child and adult groups separately. Nevertheless,
Karlowski 1975a and Coulehan 1974a used two different doses
within the same trials, that is, with the same outcome definitions.
Coulehan found that for school children, 2 g/day caused about
twice the benefit of 1 g/day. Karlowski found that for adults, 6
g/day was associated with a double benefit compared with 3 g/
day and variance analysis showed that the linear trend over the 0
g/day, 3 g/day and 6 g/day doses was significant (Hemilä 1996a;
Hemilä 1999a). Although these findings do not establish dose de-
pendency, they support the examination of doses higher than 1 g/
day and comparing different doses.
Regular vitamin C administration also led to decrease in cold sever-
ity when measured as days indoors or days off work or school, and
when measured on severity score scales (Analysis 3.1).
As regards the severity of colds, the Pitt 1979 paper is of further
interest. This was a randomised, placebo-controlled, double-blind
trial with 674 marine recruits during an eight-week period using
2 g/day of vitamin C. There was no difference in common cold
incidence and only a 2% reduction in the duration of colds and a
5% reduction in cold severity (P = 0.023) for those in the vitamin
C group. However, eight recruits developed pneumonia as a sequel
to their colds and only one of these was in the vitamin C group
(P = 0.044, Hemilä 2004; Hemilä 2007). Thus, in addition to
the common cold, vitamin C might also affect other respiratory
infections either independently of colds, or as complications of
colds (Hemilä 1999b). A further important finding in the Pitt
1979 trial was that, although the vitamin C tablets were shown to
be indistinguishable from the placebo tablets, 6% (40 out of 674;
P = 0.013) of participants correctly inferred vitamin C or placebo
tablets on the basis of subjective observations, indicating that this
proportion of participants could identify vitamin C purely on the
basis of its physiological effects (Hemilä 2006a).
Common cold duration and severity:
therapeutic trials
Since the regular supplementation trials have unambiguously
shown that vitamin C affects the duration and severity of colds
without changing their incidence in the general population, it
would seem rational to administer vitamin C therapeutically, start-
ing immediately after the first symptoms. However, the therapeu-
tic trials have mostly been negative (Analysis 4.1; Analysis 5.1).
The pooled estimates for the duration and severity of colds do not
show any difference between vitamin C and placebo.
Technically the therapeutic trials are in several ways much more
complicated than regular supplementation trials. If the timing of
supplementation initiation, the duration of supplementation, or
the dosage, influence the size of the benefit, false negative findings
might result from inappropriate study protocols.
Cowan 1950 used a therapeutic dose of about 3 g/day in the
first two days of illness with no effect on common cold duration.
Elwood 1977, Tyrrell 1977 and Audera 2001a used a three-day
supplementation, and none of them found benefit of vitamin C
on common cold duration. However, in their therapeutic trial,
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Tyrrell 1977 found a 40% reduction (P = 0.04) in the incidence of
recurrent colds in men during the trial suggesting a beneficial effect
in the way of protecting against new colds (Hemilä 1997a). A five-
day therapeutic trial by Anderson 1975a found a 25% reduction
in ’days spent indoors per subject’ because of illness (P = 0.05)
in the vitamin C group (1 to 1.5 g/day). Also, using a five-day
therapeutic supplementation of 3 g/day in a 2 x 2 factorial design
trial, Karlowski 1975c found that colds were 0.73 days shorter (P
= 0.10; Hemilä 1996a). The benefits in the five-day studies by
Anderson and Karlowski suggest that two to three days might be
too short a time for vitamin C to produce unambiguous benefits.
However, Abbott 1968 used up to two week supplementation, yet
found no therapeutic benefit of 3 g/day vitamin C. Nevertheless,
it seems clear that future therapeutic trials should not use short
supplementation, i.e. less than five days.
It is also possible that the rapidity of initiation of vitamin C sup-
plementation may have an impact on the effect. Asfora 1977 gave
the same participants either vitamin C (6 g/day for five days) or
other medications (aspirin, etc.) during different common cold
episodes, but not in a double-blinded design. When treatment
started within 24 hours of the onset of symptoms, the mean dura-
tion of vitamin C treated colds was 3.6 days, whereas the duration
was 6.9 days with the other medications (Hemilä 2006a). How-
ever, if vitamin C was initiated later than 24 hours following the
onset of symptoms, there was no meaningful difference between
the groups. Regnier 1968 concluded from his therapeutic study
that “the sooner the better” and “vitamin C administration is not
effective when started on the third or fourth day or later in the viral
infection.” Anderson 1974f found a benefit from an 8 g vitamin
C dose compared with a 4 g dose when administered only on the
first day of illness, which is also consistent with the possibility that
rapid initiation with high doses might be essential.
In several therapeutic trials, tablets were given to participants to
be taken at home so they could start taking them as soon as they
experienced the first symptoms of what they anticipated would
be a cold (Anderson 1975a; Audera 2001a; Cowan 1950; Elwood
1977; Tyrrell 1977). In the Karlowski 1975c trial “if a cold devel-
oped, the volunteers were instructed to return to have their symp-
toms and clinical observations recorded and to receive supplemen-
tal study drug to be taken” and thus there was an unknown delay
between the onset of symptoms and the initiation of treatment.
Tebrock 1956 carried out their trial “on participants reporting
to several outpatient industrial clinics under the supervision of
the physicians conducting the study” indicating a delay between
symptom onset and treatment. In the briefly described Abbott
1968 trial, it seems that the tablets were administered by the doc-
tors taking part in the trial and the average time between symptom
onset and treatment initiation remains unknown. Consequently,
even though the time between symptom onset and treatment ini-
tiation may influence the benefit of vitamin C, the data on this
factor are limited.
The larger effect observed using 8 g compared with 4 g as a single
dose in the Anderson 1974f trial and the dose dependency in
the Karlowski 1975a trial (Hemilä 1996a; Hemilä 1999a; Hemilä
2006a) suggest that future therapeutic trials with adults should
use doses of at least 8 g/day. Similarly, the greater reported benefit
of 2 g/day than 1 g/day in the prophylactic Coulehan 1974a trial
suggests that therapeutic trials with children should use doses of
at least 2 g/day.
None of the therapeutic trials examined the effect of vitamin C on
children, although children have a substantially higher incidence
of the common cold. Furthermore, the effect of regular vitamin C
on the duration of colds has been substantially greater in children,
up to 18% reduction in duration by 1 g or 2 g/day, compared with
adults (8%), which also motivates therapeutic trials in particular
with children. Finally, although a tablet is a practical and the most
common form of administering vitamin C, it is worth noting that
administering vitamin C powder directly into the nose has also
been proposed (Gotzsche 1989).
Nevertheless, while the pooled results of our therapeutic trials do
not justify routine vitamin C supplementation for the average per-
son as a therapy for the common cold, the regular supplementa-
tion trials have shown unambiguously that vitamin C has a physi-
ological effect on the duration and severity of colds. Furthermore,
the results of controlled trials and the pooled results of trials apply
to the average of the groups. We expect different sizes of vitamin
C effects in different people, some having greater and some hav-
ing smaller benefits than the average. Thus, given that vitamin
C is safe and inexpensive, it does not seem unreasonable to test
the effect of vitamin C on an individual basis as a therapy for the
common cold soon after the onset of symptoms.
Trials with no data suitable for our meta-
analyses
Seven studies did not report data suitable for our meta-analyses
(Table 1). The findings in these trials were inconsistent. Although
these trials should not be ignored, they do not add substantially
to the findings of our meta-analyses discussed above.
Laboratory studies
Three experimental studies have examined the effect of vitamin
C on experimentally induced common cold infections (Table 2).
These trials which differed in their method of exposing volunteers
to the infecting virus, are instructive. The study by Dick 1990,
which has only been reported in conference proceedings, paid care-
ful attention to the severity of the colds experienced by those who
acquired them from fellow volunteers, who had been inoculated
with a known rhinovirus. They also found that in these more nat-
ural circumstances of acquiring the virus, fewer, but not signifi-
cantly fewer, volunteers on vitamin C developed cold symptoms
but demonstrated similar viral shedding to the placebo group. The
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fragmentary descriptions of the Dick studies indicate a biologi-
cal effect of vitamin C on experimentally caused colds. Schwartz
1973 found a reduction in common cold severity in the vitamin
C group, also indicating a biological effect.
Findings in the excluded studies
Exclusion of a trial does not mean that the trial is necessarily un-
informative. For example, we used a limit of 0.2 g/day for vita-
min C as a pragmatic choice. If a trial with a lower dose finds a
negative result, the negative findings can be attributed to the low
dose. However, if a low dose does cause an effect, the effect may be
explained, for example, by a particularly low dietary intake level
(see above). Similarly, if a trial that has no placebo finds no differ-
ence between the intervention and control groups, it is not reason-
able to explain the lack of difference by the placebo effect. Finally,
since we were interested specifically in vitamin C, we excluded
multiple antioxidant trials from our meta-analyses. However, if a
multi-antioxidant formula has no effect on the common cold, it
seems justified to conclude that there is a lack of effect by each
constituent of the supplement (i.e. the finding is negative also for
vitamin C if it is one of the components). In contrast, if a multi-
antioxidant does have a beneficial effect, we cannot draw specific
conclusions since the effect can be caused by any single antioxi-
dant or the combination of several of them together. Therefore,
the excluded trials can yield meaningful information. We do not
summarise the findings of the excluded studies, but encourage the
reader to look at those trials themselves.
Heterogeneity in the effects of vitamin C
A major finding of Analysis 1.1 was statistically significant hetero-
geneity in the effect of vitamin C supplementation on common
cold incidence, indicating that vitamin C may influence common
cold in some particular conditions.
Furthermore, Anderson 1972 found about an 8% increase in the
proportion of participants who were ’not ill during the trial’, ’not
confined to the house’ and ’not off work’ in the vitamin C group.
Accordingly, about one participant in 12 benefited from vitamin
C supplementation in this particular setting (number needed to
treat to benefit (NNTB) 12; Hemilä 2006a). Participants in this
Canadian trial were asked not to enrol in the trial unless they nor-
mally experienced at least one cold in the wintertime and in this
respect the participants do not represent the average population.
Coulehan 1974a studied Navajo school children and found a 16%
higher proportion of children in the vitamin C group who were
’never ill on active surveillance’ by a medically trained clerk or
school nurse (NNTB 6; Hemilä 2006a). Thus, these two trials
indicate that some individual participants of the two studied pop-
ulations may have benefited, even though there is strong evidence
that regular vitamin C does not affect the average incidence of
colds in the general community (Figure 2).
In close parallel with vitamin C, lipid-soluble vitamin E is in-
teresting as these two antioxidants interact. Vitamin C reduces
the oxidised form of vitamin E under in vitro conditions (Hemilä
2006a) and modifies the vitamin E effect on mortality of older
males (Hemilä 2009b). Therefore heterogeneity in the vitamin E
effect on common cold incidence (Hemilä 2006b) and on pneu-
monia incidence (Hemilä 2011) is relevant when considering the
plausible heterogeneity of vitamin C effects on respiratory infec-
tions.
If the effects of vitamin C vary substantially between different
subpopulations, the heterogeneity of the effect means a need for a
careful consideration of goals when planning new trials. Assuming
heterogeneity, further trials should try to identify and characterise
the population groups or living conditions in which vitamin C
might be beneficial, rather than re-examining the effects on ordi-
nary Western people for whom the numerous trials already pub-
lished have not found any substantial overall benefits from daily
supplementation. Also, the notion that various factors may mod-
ify the effects of antioxidants is fundamentally important in re-
stricting broad generalisations from individual trials, irrespective
of whether the finding is positive or negative, and whether or not
the trial is large and carefully conducted.
Potential for bias in the common cold trials
Even though shortcomings in the design and conduct of trials can
lead to erroneous conclusions, a recent meta-analysis of 276 ran-
domised controlled trials found that double-blinding and alloca-
tion concealment, two quality measures that are frequently used
in meta-analyses, were not associated with treatment effects (Balk
2002). Furthermore, there is evidence that the importance of the
placebo effect has been substantially exaggerated (Hrobjartsson
2010).
Nevertheless, we consider that given the expected small effects of
vitamin C and the greatly subjective outcome definitions, only
placebo-controlled trials can yield information of adequate rigour
to meet the objectives of our review. Although we required only
placebo control as an inclusion criterion, essentially all of the trials
we identified were double-blind and randomised (Figure 1). Sen-
sitivity analyses showed that our conclusions were not affected by
the few trials that were methodologically less satisfactory.
Chalmers 1975 proposed that the effect of vitamin C on the com-
mon cold might be explained by “the result of the power of sug-
gestion.” As a support to this proposal he referred to the Karlowski
1975a trial in which the placebo was made of lactose which is
sweet and thus it could be distinguished by taste from ascorbic acid
which was used in vitamin C capsules. However, it was shown that
Karlowski’s findings cannot be logically explained by the break-
ing of the blind code (Hemilä 1996a; Hemilä 2006a). Further-
more, in the great majority of other trials, placebo has contained
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citric acid which cannot be distinguished from ascorbic acid by
taste and in most trials the indistinguishability of the vitamin C
and placebo preparations was explicitly stated (Figure 1). Thus,
Chalmers’ proposal is refuted by the indistinguishability of vita-
min C and placebo preparations in numerous double-blinded tri-
als.
Some aspects of this Cochrane Review were commented on re-
cently by two groups of commentators, to which Hemilä replied
(Shamseer 2008).
Safety of vitamin C
None of the vitamin C common cold trials that reported on adverse
effects found evidence that vitamin C might be harmful in doses
that were tested.
In general, vitamin C is considered safe in doses up to several
grams per day. Although there has been speculation about the
potential harm of large doses, it has been shown to be unfounded
(Dykes 1975; Hemilä 2006a). For example, while 0.01 g/day of
vitamin C protects against scurvy, in a recent pharmacokinetic
study participants were administered up to 100 g of vitamin C
intravenously within a few hours without any reported adverse
effects, indicating the safety of such a very large dose in healthy
people (Padayatty 2004).
Bee 1980 proposed 10 to 15 g/day for treating colds and Cathcart
1981 reported that he had orally administered over 30 g/day vita-
min C to common cold patients. Such reports indicate the safety
of such high doses, even though uncontrolled observations do not
provide valid evidence of benefit. There are few reports of severe
harm caused by high-dose vitamin C administration, but they can
usually be attributed to some other coinciding medical condition.
For example, the death of a 68-year old African American man
was not attributed to intravenous injection of 80 g of vitamin C
on two consecutive days per se but to his coincident glucose-6-
phosphate dehydrogenase deficiency (Campbell 1975).
Linus Pauling’s contribution
Among the four trials included in the Pauling 1971a meta-anal-
ysis, the largest dose, 1 g/day, was used by Ritzel 1961. Pauling
based his optimistic quantitative expectations on this rather small
and short trial, which was randomised, double-blind and placebo-
controlled. Ritzel found significant reduction in the incidence (-
45%) and duration (- 31%) of colds, and Pauling calculated a
combination of the duration and incidence, which he labelled ’in-
tegrated morbidity’, referring to the total sickness days per person
during the trial.
The ’integrated morbidity’ was reduced by 61% in the Ritzel trial,
and Pauling 1971a used this finding to extrapolate the effect of
vitamin C to a broader community. The present analysis suggests
that ’integrated morbidity’ is not a good outcome measure, since
the effects on incidence and duration/severity seem to have quite
different patterns, though in the case of the Ritzel study, they
moved together.
Ritzel carried out his trial with school children in a skiing school in
the Swiss Alps, and such children are not a representative selection
of the general population. In our analysis, Ritzel’s trial is included
in the group of five trials with participants exposed to short phys-
ical stress (Figure 2) which highlights the special character of this
trial. Thus, it was not a misjudgement by Pauling 1971a to put
the greatest weight on this trial, but his error was to extrapolate
the findings to the general population (Hemilä 1997b; Hemilä
2006a).
Pauling pointed out various errors in the influential review by
Dykes 1975, but did not contribute thereafter to the vitamin C
and common cold field (Pauling 1976b; Pauling 1976c).
Pauling’s vigorous advocacy was undoubtedly the stimulus for the
wave of methodologically good trials, which now enable us to
understand better the rather confusing role that vitamin C plays
in the defence against the common cold. Significant uncertainties
still persist, which further research should clarify.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The lack of effect of regularly administered vitamin C on the inci-
dence of the common cold in the general population throws doubt
on the usefulness of this practice. In special circumstances, where
people are engaged in extreme physical exertion or exposed to sig-
nificant cold stress, or both, vitamin C supplementation seems to
have a beneficial prophylactic effect, but caution should be exer-
cised in generalising this finding.
The regular supplementation trials found that ≥ 0.2 g/day vitamin
C reduced common cold duration by 8% in adults and by 14%
in children, and 1 to 2 g/day vitamin C reduced common cold
duration by 18% in children. The practical relevance of these
findings is not clear. In our opinion, this level of benefit does
not justify long-term supplementation in its own right. So far,
therapeutic supplementation has not been shown to be effective.
Nevertheless, given the consistent effect of vitamin C on common
cold duration and severity in the regular supplementation studies,
and the low cost and safety, it may be worthwhile for common
cold patients to test on an individual basis whether therapeutic
vitamin C is beneficial for them.
Implications for research
It does not seem worthwhile to carry out further regular supple-
mentation trials in the general population. However, the findings
in marathon runners, skiers, swimmers and soldiers operating in
subarctic conditions warrant further research.
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None of the therapeutic trials carried out so far have examined the
effect of vitamin C on children, even though the regular supple-
mentation trials have found substantially greater benefit for chil-
dren than for adults. Furthermore, the incidence of the common
cold in children is substantially higher in children compared with
adults. Therefore, therapeutic trials are warranted in particular in
children.
The findings in the Anderson 1974a study on the greater benefit
of a single 8 g dose compared with a 4 g dose on the first day of the
common cold, and the findings of the Karlowski 1975a trial on
the greater benefit of 6 g/day compared with 3 g/day, suggest that
doses in further therapeutic trials with adults should be at least 8
g/day.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abbott 1968
Methods Double-blind RCT, treatment trial
Participants Family members of 78 UK general practitioners. Males and females were in equal num-
bers; 52% were from 21 to 50 years. 147 vitamin C; 123 placebo (p 442)
Interventions 3 g/d vitamin C as effervescent tablets (1 g 3 times per day) was “started as soon as coryza
symptoms appeared and continued for as long as necessary, up to a total of fourteen
days”




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “similar placebo tablets were prepared”
Anderson 1972
Methods Double-blind RCT. Regular supplementation trial. Duration 3 months
Participants Canadian adults, both sexes. 407 vitamin C; 411 placebo. Recruitment specified previous
cold proneness in the winter months
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Anderson 1972 (Continued)
Interventions 1 g/d vitamin C and 3 g/d extra for the first 3 days of illness
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk [Vitamin C tablets:] “The taste of this
formulation was well matched by a
placebo preparation...The effectiveness of
the matching was established by asking 30
individuals to taste both tablets ...”
Anderson 1974a
Methods Double-blind RCT. Duration 3 months. 4 regular supplementation, 2 treatment and 2
placebo arms
This entry reports a regular supplementation arm
Participants Canadian adults, both sexes. Data for this arm include 277 vitamin C; 285 placebo
Interventions 1 g/d vitamin C and 4 g/d at onset of illness on the 1st day only
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes Problems with the placebo group #6; see p 40 (Table 16) in Hemilä 2006a. Therefore
comparison in this review is restricted to the placebo group #4 which had close baseline
values for “usual days indoors” and “usual days off work” and “contact with children”
consistent with the baseline values in the 6 vitamin C groups
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Anderson 1974a (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk Tablets: “taste test carried out with the help
of a number of colleagues demonstrated
that they were reasonably well matched in
flavour, texture and appearance”
Anderson 1974b
Methods See Anderson 1974a. Regular supplementation arm
Participants 275 vitamin C
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
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Anderson 1974b (Continued)








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Anderson 1974c
Methods See Anderson 1974a. Regular supplementation arm
Participants 308 vitamin C
Interventions 2 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
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Anderson 1974d
Methods See Anderson 1974a. Regular supplementation arm
Participants 331 vitamin C
Interventions 0.25 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Anderson 1974e
Methods See Anderson 1974a. Therapeutic arm
Participants 275 vitamin C
Interventions 4 g/d vitamin C on the 1st day of illness only
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Anderson 1974e (Continued)
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Anderson 1974f
Methods See for Anderson 1974a. Therapeutic arm
Participants 308 vitamin C
Interventions 8 g/d vitamin C on the 1st day of illness only
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
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Anderson 1974f (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Anderson 1975a
Methods Double-blind RCT. Therapeutic trial. Duration 15 weeks. 2 active and 1 placebo arm
This arm used vitamin C tablets
Participants Canadian adults, both sexes. 150 vitamin C; 146 placebo
Interventions 0.5 g weekly and 1.5 g/d on the 1st day of illness and 1 g/d for the next 4 days
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes Indistinguishability of treatments: (p 824) “three types of medication were used: a 500-
mg tablet containing sodium and calcium ascorbate in an approximate 2:1 ratio, a placebo
tablet of the same appearance and taste, and a capsule containing 500 mg of ascorbic
acid in sustained-release form. ... It was not possible to obtain placebo capsules that
were truly indistinguishable from the active sustained-release form because the contents
of the capsules (ascorbic acid pellets) proved prohibitively expensive to imitate. The
explanatory notes provided to the subjects were therefore deliberately phrased to give the
impression that, as with the tablets, half of the capsules contained a placebo preparation.
This subterfuge was successful ... ”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk See Notes above
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Anderson 1975b
Methods See Anderson 1975a. This arm used vitamin C capsules
Participants 152 vitamin C
Interventions See Anderson 1975a
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Asfora 1977
Methods Initiated as a double-blind trial. Therapeutic trial
Participants Participants with age range between 14 and 89. 42 vitamin C; 41 placebo
Interventions 6 g/d vitamin C for 5 d (total 30 g)
Outcomes Clinical progress (Table 1)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Asfora 1977 (Continued)
Random sequence generation (selection
bias)
Unclear risk “preparations were given to alternate pa-
tients”
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Audera 2001a
Methods Double-blind RCT. Therapeutic trial
Participants Australian adults of both sexes. 47 vitamin C; 42 placebo
Interventions 1 g/d vitamin C for 3 days. Placebo group received 30 mg/d vitamin C daily for 3 days
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Audera 2001a (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “tablets with identical appearance and packag-
ing”
Audera 2001b
Methods See Audera 2001a
Participants 50 vitamin C
Interventions 3 g/d vitamin C for 3 days
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Bancalari 1984
Methods Double-blind RCT. Regular supplementation trial. Duration 84 days
Participants Chilean school children, male and female, age 10 to 12 years. 32 vitamin C; 30 placebo
Interventions 2 g/d vitamin C
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Bancalari 1984 (Continued)
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “vitamin C tablets and the placebo tablets
were identical in colour, taste, size and con-
sistency”
Briggs 1984
Methods Double-blind RCT. Regular supplementation trial. Over 8 winters for 3 or 6 months of
commitment by each volunteer
Participants Australian adults, male and female. 265 vitamin C; 263 placebo
Interventions 1 g/d vitamin C plus 4 g/d when respiratory symptoms occurred. Placebo group received
50 mg/d plus 200 mg/d when ill
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and it was estimated as SD = mean
Risk of bias
Bias Authors’ judgement Support for judgement
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Briggs 1984 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “identical opaque gelatin capsules (dark
brown) and ... similar acidic taste, but lack-
ing vitamin C activity. Citric acid was se-
lected”
Brown 1945
Methods Placebo-controlled alternative-allocation trial. Therapeutic trial
Participants US college students. 179 vitamin C, 119 placebo; 206 with nose colds and 92 with
throat colds
Interventions 1 g vitamin C at first examination at the start of the cold and then 1 g 24 hours later
Outcomes “Colds that did not develop” meaning that the cold lasted only a day. In contrast, those
who still had symptoms on the next day were considered to have a cold. (Table 1)
Notes Alternate allocation is not consistent with the distribution of participants in the vitamin
C and placebo groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “alternately”
Allocation concealment (selection bias) Unclear risk ?
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “given... without knowledge on the sub-
jects’ part that placebos were being given.”
Indicates single-blinding
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Brown 1945 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Subjects’ observed outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ?
Vitamin C and placebo indistinguishable? Low risk “citric acid as a placebo”
Carr 1981a
Methods Double-blind RCT. Regular supplementation trial. Duration 100 days. Identical twins:
one group living together and the other living apart. This deals with those living together
Participants Australian males and females age range 14 to 64 years (mean 25 years). 51 twin pairs
living together
Interventions 1 g/d vitamin C. Both groups received a multi-vitamin tablet containing 70 mg/d vitamin
C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes SD for duration was not published and the SD was calculated from the P value
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “matching of the active and placebo tablets
was checked for both appearance and taste”
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Carr 1981b
Methods See Carr 1981a. This deals with those living apart
Participants 44 twin pairs living apart
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “matching of the active and placebo tablets
was checked for both appearance and taste”
Carson 1975
Methods Double-blind RCT. Regular supplementation trial. Duration 40 days
Participants UK adults. 121 vitamin C; 123 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Carson 1975 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “tablets or matching lactose dummies”
Charleston 1972
Methods Single-blind, not randomised. Regular supplementation trial. Duration 15 weeks
Participants Staff and students of the University of Strathclyde, UK. 47 vitamin C; 43 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk ?
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were blinded
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Charleston 1972 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “placebo similar in appearance but contain-
ing lactose and 5% citric acid”
Clegg 1975
Methods Double-blind RCT. Regular supplementation trial. Duration 15 weeks
Participants Scottish students. 67 vitamin C; 70 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “The placebo and ascorbic acid tablets were
organoleptically indistinguishable”
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Constantini 2011a
Methods Double-blind RCT. Regular supplementation trial
Participants Male competitive swimmers in Israel. 12 vitamin C; 10 placebo
Interventions 1 g/day vitamin C for 3 months
Outcomes Incidence of colds. Duration of colds (Analysis 2.1), severity of colds (Analysis 3.1)
Notes Trial is divided into males and females since there was significant heterogeneity in vitamin
C effect (P = 0.003)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly selected plastic bottle”
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “identical in appearance”
Constantini 2011b
Methods Double-blind RCT. Regular supplementation trial
Participants Female competitive swimmers in Israel. 9 vitamin C, 8 placebo
Interventions 1 g/day vitamin C for 3 months
Outcomes Incidence of colds. Duration of colds (Analysis 2.1), severity of colds (Analysis 3.1)
Notes Trial is divided into males and females since there was significant heterogeneity in vitamin
C effect (P = 0.003)
Risk of bias
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Constantini 2011b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
Coulehan 1974a
Methods Double-blind, alternate allocation. Regular supplementation trial. Duration 14 weeks
Participants USA. Students at a Navajo Indian school. Older residential students. 131 vitamin C;
128 placebo
Interventions 2 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and it was estimated as SD = mean
Personal communication (13 September 1995), about table 4: “... you are right, it is
quite obvious that there is a typographical error. What I am referring to in those columns
is the number of children without days of sickness, rather than the number of days as
such. The title of Table 4 is correct, but the labelling of the columns is incorrect.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation was “alternatively, from an al-
phabetical listing by classroom to one of
two study groups”
Allocation concealment (selection bias) Low risk Double-blind
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Coulehan 1974a (Continued)








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “Placebos were formulated from citric acid
to be indistinguishable in taste and appear-
ance from the vitamin C tablets”
Coulehan 1974b
Methods See Coulehan 1974a
Participants Younger residential students. 190 vitamin C; 192 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and it was estimated as SD = mean
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ?
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk
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Coulehan 1976
Methods Double-blind RCT. Regular supplementation trial. Duration 18 weeks in one school
and 15 weeks in another
Participants USA. Children at 2 Navajo Indian residential schools, age 6 to 15 years. Both sexes. 428
vitamin C; 428 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and it was estimated as SD = mean
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “placebo tablets were formulated with citric
acid to be identical in appearance and taste
with ascorbic acid pills”
Cowan 1942
Methods Placebo-controlled, allocation method not clear. Regular supplementation trial. Dura-
tion 28 weeks
Participants US college students. 208 vitamin C; 155 placebo
Interventions 0.2 g/d vitamin C
Outcomes Incidence (Analysis 1.1)
Notes SD for duration was not published and it was estimated as SD = mean
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Cowan 1942 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The students were assigned alternately and
without selection to an experimental and to
a control group.” However, the discrepancy
in the size of trial arms is not consistent with
alternate allocation, see above (208 versus
155)
Allocation concealment (selection bias) Unclear risk ?
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Single-blinded: “... placebo tablets of the
same size, shape, appearance and taste as
the ascorbic acid tablets. These students, of
course, did not know that they were serving
as controls.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The students (who were blinded) were in-
structed to report whenever a cold devel-
oped
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ?
Vitamin C and placebo indistinguishable? Low risk “... placebo tablets of the same size, shape,
appearance and taste as the ascorbic acid
tablets. These students, of course, did not
know that they were serving as controls.”
Cowan 1950
Methods Probably double-blind RCT. Alternate allocation. Therapeutic trial
Participants US college students. 76 vitamin C; 77 placebo
Interventions 0.67 g of vitamin C for every 4 hours, with a maximum of 10 doses (total 6.7 grams); i.
e. about 3 g/d for 2 days
Outcomes Duration (Analysis 4.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Cowan 1950 (Continued)
Random sequence generation (selection
bias)
Unclear risk “The medicaments were given out in strict
rotation to the students as they enrolled”
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “Placebo (citric acid to simulate the taste
of ascorbic acid, lactose, cornstarch, sugar,
talc and stearic acid)”
Dahlberg 1944
Methods Double-blind RCT. Regular supplementation trial. Duration 57 days
Participants Swedish army. 1259 vitamin C; 1266 placebo
Interventions 0.2 g/d vitamin C during the first 24 days; 50 mg/d thereafter
Outcomes Incidence Analysis 1.1
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Dahlberg 1944 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “Control tablets, to which a suitable
amount of citric acid had been added, to
disguise any difference in taste”
Dick 1990
Methods Double-blind, placebo-controlled trial. Brief abstract report of 3 experimental regular
supplementation studies using intense exposure to infected volunteers
Participants USA, adult volunteers. 24 vitamin C; 24 placebo
Interventions 2 g/d vitamin C
Outcomes Shown in Table 2. Not included in meta-analyses
Notes 3 abstracts, no full paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ?
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
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Elliot 1973
Methods Double-blind RCT. Regular supplementation trial
Participants Members of the crew of a Polaris submarine; 37 vitamin C, 33 placebo
Interventions 2 g/d vitamin C for 10 weeks
Outcomes Incidence of runny nose or sneezing. Man-days of morbidity for hoarseness, sore throats,
non-productive coughs and productive coughs (Table 1)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “Both AA and placebo [citric acid] capsules
looked identical and when opened the con-
tents were similar in taste and appearance”
Elwood 1976
Methods Double-blind RCT. Regular supplementation trial
Participants Wales, young mothers. 339 vitamin C; 349 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
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Elwood 1976 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “tablets ... These contained either 1 g ascor-
bic acid in an effervescent base or a match-
ing placebo”
Elwood 1977
Methods Double-blind RCT. Therapeutic trial
Participants Wales, young mothers. 145 colds treated with vitamin C; 119 with placebo
Interventions 4 g/d vitamin C daily for the first 2.5 days of illness
Outcomes Duration (Analysis 2.1)
Colds were classified either as simple or chest colds
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Elwood 1977 (Continued)




Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Franz 1956
Methods Double-blind. Regular supplementation study. 2 x 2 factorial: vitamin C and flavonoids.
Duration 3 months
Participants Medical students and student nurses. 44 vitamin C; 45 no vitamin C
Interventions 0.2 g/d vitamin C
Outcomes Incidence (Analysis 1.1)
Notes In the vitamin C group 93% (13/14) of colds were cured or improved in 5 days versus
53% (8/15) in the no vitamin C group (P = 0.03; see p 14 Hemilä 2006a)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Groups were assigned in rotation”
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk Tablets: “all looked and tasted alike”
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Himmelstein 1998a
Methods Double-blind RCT. Regular supplementation trial. Duration 3 months
Participants US sedentary people. 23 vitamin C; 25 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes A parallel trial with marathon runners is excluded from our analysis, because the drop-
out rate was very high and divergent in the trial arms (Himmelstein 1998b)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “Placebo (similar looking and tasting
tablets containing lactose)”
Karlowski 1975a
Methods Double-blind RCT. 2 x 2 factorial: regular supplementation and therapeutic vitamin C.
Duration 9 months. We compared 3 different arms with the placebo arm. This is regular
supplementation arm
Participants USA, employees of the NIH. 44 vitamin C; 46 placebo
Interventions 3 g/d vitamin C
Outcomes Duration (Analysis 2.1)
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Karlowski 1975a (Continued)
Notes The authors believed that the benefits observed were attributable to the breaking of
the patient blind: “we discovered that some of the volunteers had tasted the contents
of their capsules and professed to know whether they were taking the ascorbic acid or
the placebo”. However, their interpretation was later shown to be erroneous, see Hemilä
1996a, Hemilä 2006a, Hemilä 2006c
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk See Notes
Karlowski 1975b
Methods See Karlowski 1975a. This is regular supplementation plus therapeutic arm
Participants 57 vitamin C
Interventions 3 g/d vitamin C and 3 g/d therapeutic from the onset of cold for 5 days
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
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Karlowski 1975b (Continued)
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Karlowski 1975c
Methods See Karlowski 1975a. This is therapeutic only arm
Participants 43 vitamin C
Interventions 3 g/d therapeutic vitamin C from the onset of cold for 5 days
Outcomes Duration (Analysis 4.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
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Karlowski 1975c (Continued)
Vitamin C and placebo indistinguishable? Unclear risk ?
Liljefors 1972
Methods Double-blind RCT. Cross-over regular supplementation trial. Duration 2 + 2 weeks.
In the first 2 weeks 25 participants received vitamin C and 18 placebo. As participants
became ill they were removed from the trial and 3 people withdrew. In the second period,
18 received placebo and 8 vitamin C
Participants Swedish army males. 33 vitamin C; 33 placebo
Interventions 2 g/d vitamin C for 2 weeks
Outcomes Incidence (Analysis 1.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Ludvigsson 1977a
Methods Double-blind RCT. Regular supplementation trial. Duration 7 weeks
Participants Swedish school children. 80 vitamin C; 78 placebo
Interventions 1 g/d vitamin C. Placebo contained 30 mg/d vitamin C
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Ludvigsson 1977a (Continued)
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes Pilot study to Ludvigsson 1977b
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “fizzy tablet which contained 1000 mg vi-
tamin C; in the other group the fizzy tablet
looked and tasted the same”
Ludvigsson 1977b
Methods Double-blind RCT. Regular supplementation trial. Duration 3 months
Participants Swedish school children. 304 vitamin C; 311 placebo
Interventions 1 g/d vitamin C. Placebo contained 10 mg/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
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Ludvigsson 1977b (Continued)
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “fizzy tablet which contained 1000 mg vi-
tamin C; in the other group the fizzy tablet
looked and tasted the same”
Miller 1977a
Methods Double-blind RCT. Regular supplementation trial. Identical twins. Duration 5 months
Participants US school children. 12 twin pairs “high body weight”
Interventions 1 g/d vitamin C. Placebo contained 50 mg/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
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Miller 1977a (Continued)
Vitamin C and placebo indistinguishable? Unclear risk ?
Miller 1977b
Methods See Miller 1977a
Participants 12 twin pairs “medium body weight”
Interventions 0.75 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Miller 1977c
Methods See Miller 1977a
Participants 20 twin pairs “low body weight”
Interventions 0.5 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
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Miller 1977c (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Moolla 1996a
Methods Double-blind RCT. Regular supplementation trial. Duration 6 weeks before and 2 weeks
after the race
Participants South Africa. Ultra marathon runners. 13 vitamin C; 19 placebo
Interventions 0.25 g/d vitamin C
Outcomes Incidence (Analysis 1.1)
Notes 1/4 of those who reported respiratory symptoms in the vitamin C group, and 8/13
of those who reported respiratory symptoms in the placebo group, reported that their
respiratory symptoms were severe (P = 0.08)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Moolla 1996a (Continued)








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “placebo was identical in form to the ascor-
bic acid”
Moolla 1996b
Methods See Moolla 1996a
Participants Sedentary controls for marathon runners. 11 vitamin C; 19 placebo
Interventions 0.25 g/d vitamin C
Outcomes Incidence (Analysis 1.1)
Notes 0/6 of those who reported respiratory symptoms in the vitamin C group and 4/7 of those
who reported respiratory symptoms in the placebo group reported that their respiratory
symptoms were severe (P = 0.02)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
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Moolla 1996b (Continued)
Vitamin C and placebo indistinguishable? Low risk “placebo was identical in form to the ascorbic acid”
Peters 1993a
Methods Double-blind RCT. Regular supplementation trial. Duration 3 weeks before and 2 weeks
after the race
Participants South Africa. Ultra marathon runners. 43 vitamin C; 41 placebo
Interventions 0.6 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “identical looking and tasting placebo con-
taining citric acid”
Peters 1993b
Methods See Peters 1993a.
Participants Sedentary controls for marathon runners. 34 vitamin C; 39 placebo
Interventions 0.6 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “identical looking and tasting placebo containing citric acid”
Peters 1996a
Methods Double-blind RCT. Regular supplementation trial. Duration 21 days prior to the race
Participants South Africa. Ultra marathon runners. 44 vitamin C; 47 placebo
Interventions 0.5 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and it was estimated as SD = mean
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Peters 1996a (Continued)




Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “tablets of similar appearance”
Peters 1996b
Methods See Peters 1996a.
Participants South Africa. Family controls for marathon runners. 41 vitamin C; 45 placebo
Interventions 0.5 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “tablets of similar appearance”
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Pitt 1979
Methods Double-blind RCT. Regular supplementation trial. Duration 8 weeks
Participants USA marine recruits. 331 vitamin C; 343 placebo
Interventions 2 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes SD for duration was not published and it was estimated as SD = mean
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “the placebo tablets were formulated from
citric acid and were indistinguishable in
appearance and taste from the vitamin C
tablets”
Regnier 1968
Methods Initiated as a double-blind trial, but changed to a single-blind
Participants The number of participants for the double-blind part is not reported. In the single-blind
stage, 22 subjects were included “The majority were adults whose ages ranged from 30
to 50, with the extremes being five children younger than 12” (p 949)
Interventions For the double-blind part: “ascorbic acid alone, ascorbic acid plus bioflavonoids,
flavonoids only and, fourthly, a lactose placebo with the two ’vitamins’ present either
alone or together in 0.2 g quantities”. In the single-blind stage, 0.6 g of vitamin C was
administered every 3 h
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Regnier 1968 (Continued)
Outcomes Clinical progress (Table 1)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Allocation method not described
Allocation concealment (selection bias) Unclear risk ?
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Initiated as double-blind




Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ?
Vitamin C and placebo indistinguishable? Unclear risk “lactose placebo”
Ritzel 1961
Methods Double-blind RCT. Regular supplementation trial. Duration 2 weeks
Participants Children attending ski school in Swiss Alps. 139 vitamin C; 140 placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes SD for duration was not published and the SD was calculated from the P value
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Ritzel 1961 (Continued)








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “The placebo was indistinguishable from
the 1-gm ascorbic acid tablet”
Sabiston 1974
Methods Double-blind RCT. Regular supplementation trial. Duration 2 to 3 weeks
Participants Canadian male military recruits during subarctic winter exercises. 56 vitamin C; 56
placebo
Interventions 1 g/d vitamin C
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes Personal communication from Manny Radomski (12 September 2009): “Tent group
commanders [who were responsible for distributing the pills and recording the distri-
bution] did not know what was in the vials... We [the authors] collected the data by
symptoms on T-scan cards. We did not ’break the code’ until after all cards had been
assessed.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Sabiston 1974 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk Personal communication (Radomski 12
September 2009): “Vitamin C and placebo
were in identical capsules, so taste did not
enter into the equation... In our pre-brief-
ing to the troops, we believe that we told
the troops that they would all be getting
vitamin C but at different doses.”
Sasazuki 2006
Methods Double-blind RCT. Regular supplementation trial. Duration 3.5 years
Participants Japanese males and females, mean age 57 years. 140 vitamin C; 133 placebo
Interventions 0.5 g/d vitamin C. Placebo contained 50 mg/d vitamin C
Outcomes Incidence (Analysis 1.1)
ITT results are shown
Notes Additional data provided by authors
Duration and severity of colds were reported, but they were recorded on the period after
supplementation had been stopped, with no rationale described for such a comparison
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
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Scheunert 1949
Methods Prophylactic trial
Participants 1066 factory workers in Germany between November 1942 and June 1943
Interventions Different doses of vitamin C were administered to 4 study groups (range 0.02 to 0.3 g/
d) so that the lowest dose arm(s) might be used as the control group. Duration of the
study was 244 days
Outcomes The common cold [Erkältungskrankheiten] was one of the outcomes and “The percent-
age monthly duration of people sick with the common cold” is listed (Table 1)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ?
Allocation concealment (selection bias) Unclear risk ?








Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ?
Vitamin C and placebo indistinguishable? Unclear risk ?
Schwartz 1973
Methods Double-blind experimental regular supplementation study with nasal instillation of virus
after 2 weeks of pre-treatment
Participants Male US prison volunteers. 11 vitamin C; 10 placebo
Interventions 3 g/d vitamin C
Outcomes Shown in Table 2. Not included in meta-analyses
Notes -
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Schwartz 1973 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ?
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Tebrock 1956
Methods Double-blinded alternative-allocation trial. Therapeutic trial
Participants Adults from outpatient industrial clinics, and some college, seminary and private patients.
956 vitamin C, 960 placebo
Interventions 0.2 g/d vitamin C or/and flavonoids in a 2 x 2 factorial design for 3 days




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “assigned in rotation” to 8 groups
Allocation concealment (selection bias) Low risk Double-blind
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Tebrock 1956 (Continued)




Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Tyrrell 1977
Methods Double-blind RCT. Therapeutic trial
Participants UK, both sexes. 274 episodes treated with vitamin C; 329 placebo
Interventions 4 g/d vitamin C for the first 2.5 days of illness
Outcomes Duration (Analysis 4.1) and severity (Analysis 5.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk “the tubes with ’placebo treatment’, contained
inert substances of identical appearance and
taste”
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Van Straten 2002
Methods Double-blind RCT. Regular supplementation trial. Duration 60 days
Participants UK, both sexes. 84 vitamin C; 84 placebo
Interventions 1 g/d vitamin C. Ester-C ascorbate, a form that, according to authors, “allows cells to
efficiently absorb and retain high levels of vitamin”
Outcomes Incidence (Analysis 1.1) and duration (Analysis 2.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Low risk Tablets: “ascorbate 500 mg or a matched
placebo”
Walker 1967
Methods Experimental regular supplementation study in which healthy volunteers were in-
tranasally inoculated with viruses. Duration 3 days before and 6 days after nasal instil-
lation of virus
Participants UK adults both sexes. 47 vitamin C; 44 placebo
Interventions 3 g/d vitamin C
Outcomes Shown in Table 2. Not included in meta-analyses
Notes -
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Walker 1967 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ?
Allocation concealment (selection bias) Unclear risk ?








Incomplete outcome data (attrition bias)
All outcomes
Low risk Laboratory study
Vitamin C and placebo indistinguishable? Unclear risk ?
Wilson 1973a
Methods Double-blind RCT. Regular supplementation trial. Duration 9 months
Participants UK boarding school girls. 70 vitamin C; 58 placebo
Interventions 0.2 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes Complicated classification system makes comparison with other trials difficult
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised
Allocation concealment (selection bias) Low risk Double-blind
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Wilson 1973a (Continued)




Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
Wilson 1973b
Methods See Wilson 1973a
Participants UK boarding school boys. 88 vitamin C; 86 placebo
Interventions 0.2 g/d vitamin C
Outcomes Incidence (Analysis 1.1), duration (Analysis 2.1) and severity (Analysis 3.1)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk








Incomplete outcome data (attrition bias)
All outcomes
Low risk
Vitamin C and placebo indistinguishable? Unclear risk ?
g/d: grams per day
h: hours
mg/d: milligrams per day
SD: standard deviation
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ITT: intention-to-treat
NIH: National Institutes for Health
RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Audera 2001c Vitamin C was administered with flavonoids. Thus the comparison was not on vitamin C specifically. There
was no difference between placebo and 3 g/day vitamin C + flavonoid groups. 2 other arms are included in
our analyses (Audera 2001a; Audera 2001b)
Baird 1979 Low dose. 362 UK students aged 17 to 25 years were studied for 72 days in a double-blind RCT of regular
supplementation. A daily drink contained either synthetic orange juice without ascorbic acid, synthetic juice
with 0.08 g/d of ascorbic acid added, or natural orange juice with 0.08 g/d of ascorbic acid added. There
was a highly significant reduction in common cold incidence among males (RR 0.63; 95% CI 0.50 to 0.78)
but not in females (RR 1.24; 95% CI 0.95 to 1.61) (Hemilä 1997a and Hemilä 2006a). The heterogeneity
between sexes was highly significant (Hemilä 2008). The benefit of low-dose vitamin C supplementation may
be explained by low dietary vitamin C intake in the UK (Hemilä 1997a)
Barnes 1961 No placebo comparison. A trial in the USA. A multivitamin preparation that included 0.2 g/d vitamin C was
given to 23 members (10 boys, 13 girls) of a basketball team for 7 weeks; medication being received from
the coaches. The cold outcomes were compared with those of 16 people (8 boys, 8 girls) of the same age and
background. The controls reported to the coaches daily. Days sick from cold were counted in each group.
The study took place over 8 weeks during which the basketball players took medication on an average of 43
days. The only usable outcome was “mean days per person” in the vitamin C group 1.48 (SD 2.65) and in
the control group 6.87 (SD 8.57). However, there are serious doubts about the comparability of the controls
who were apparently not basketball players
Bartley 1953 Low dose. “The volunteers did not know to which group they belonged, nor did the physicians responsible
for the clinical investigations. All the volunteers were given each day 7 supplementary tablets of identical
taste and appearance, some containing vitamin C, others being dummies” (p 8). 3 participants received 0.
07 g/d vitamin C and a total of 14 cold episodes were recorded among them in the follow up, 4 participants
were administered 0.01 g/d vitamin C (18 colds), and 6 persons were administered no vitamin C (30 colds)
. The geometric mean length of colds in vitamin C deprived participants was 6.4 days, and in non-deprived
participants 3.3 days, and the authors concluded “such evidence as there is definitely confirms the hypothesis
that the absence of vitamin C tended to cause colds to last longer” (p 43)
Bendel 1955 No placebo comparison and the control group was not parallel. 120 children at a summer camp for 2 weeks
were given 0.2 g/d vitamin C daily and their cold experience was compared with that of participants in an
earlier camp
Bergquist 1943 Low dose. A Swedish trial involving supplementation with only 0.03 g/d vitamin C
Bessel-Lorck 1958 No placebo comparison. Berlin school children in a skiing camp. Abridged summary: “26 subjects received 1 g
of vitamin C daily during the first 9 days. Under this regimen only one student became sick. In 20 participants
the regular supplementation did not begin until the 9th day. At this point in time 9 students were already sick
with upper respiratory infections; and 3 others became infected within the first 3 days after the trial began. All
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(Continued)
of those who were sick were treated with 2 g of vitamin C per day. Within just 24 hours a rapid improvement
in the general condition was evident so that elevated physical demands were met without particular difficulty.
All participants displayed a significant increase in their capacity to perform physical activities while being
treated with vitamin C.” The Bessel-Lorck paper is available as a translation. This trial motivated Ritzel 1961
to carry out his RCT (see Analysis 1.1.2)
Bibile 1966 This was cited by Kleijnen 1989, but we have been unable to retrieve a copy through library orders
Boines 1956 No placebo comparison. Study of poliomyelitis sufferers
Chavance 1993 Low dose. Double-blind RCT of 0.09 g/d vitamin C in elderly participants. No benefit was demonstrated
Cuendet 1946 No placebo comparison. 200 children in 3 mountain parishes took vitamin C supplements up to 0.3 g/d
Dyllick 1967 No placebo comparison. Cohort workplace study involving 200 recipients of 1 g/d of vitamin C whose
respiratory experience was compared with those not receiving vitamin C
Fogelholm 1998 Vitamin C in combination with other antioxidants. Finnish study involving 75 athletes. RCT of 1 g/d vitamin
C with 0.3 g/d vitamin E and 0.09 g/d ubiquinone versus an undescribed placebo. Methodologically strong
study but was excluded from the meta-analyses because there were 3 antioxidants in the active preparation
which were each hypothesised to be potentially beneficial
Glazebrook 1942 Low dose. 1500 boys at a UK boarding school during World War II. The participants were allocated as
administrative units and not on an individual basis. Vitamin C (0.05 to 0.3 g/d) was added to cocoa and
milk in the kitchen to a group of 335 boys. Although ineffective powder was not added to the drinks of the
control group, the control drinks served functionally as a placebo. The number of participants who had colds
was 17% lower in the vitamin C group (72/335 versus 286/1100; P = 0.10, Hemilä 2004) and the number
of participants admitted to hospital because of the common cold was 23% lower (59/335 versus 253/1100;
P = 0.04, Hemilä 2011)
Gormly 1977 No placebo comparison. 14 males of 29 members of a 1-year Antarctic expedition took 1 g/d vitamin C
throughout their stay. Their health outcomes were compared with the remaining group who did not take
vitamin C, and no difference was observed between the 2 groups
Gorton 1999 No placebo comparison and the control group not parallel. A technical training facility in Chile was the site of
this cohort study with 250 trainees who were given 3 g/d vitamin C during their 10-day course. The vitamin
C group was compared with a control group of 463 students who had been monitored in a somewhat similar
way during the previous year (sic)
Himmelstein 1998b There was an extreme and divergent drop-out rate in the Himmelstein 1998b trial. They started with 52
marathon runners in 2 groups, but 42% (22 of 52) of the vitamin C group, and 75% (38 of 52) of the placebo
group dropped out during the trial (P = 0.003)
Hopfengärtner 1944 Low dose. Long-term hospital baby study in which supplementation of 0.05 g/d vitamin C was used
Hunt 1994 Not focused on the common cold. Double-blind RCT. 57 elderly UK patients suffering from acute bronchitis
or pneumonia who were admitted to hospital for treatment were administered 0.2 g/d of vitamin C (see
Hemilä 2007)
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(Continued)
Kimbarowski 1967 No placebo comparison. 216 Russian soldiers were hospitalised because of influenza A. 114 were administered
0.2 g/d vitamin C. There were 2 cases of pneumonia in the vitamin C group in comparison with 10 cases
in the control group. Thus this trial found a lower incidence of complications of viral respiratory infection
(Hemilä 2004; Hemilä 2007)
Koytchev 2003 No placebo comparison. Double-blind RCT involving 1167 participants. 4 arms, colds treated with 0.9 g/d
vitamin C plus or minus antihistamine and antipyretics
Maggini 2012 Vitamin C in combination with zinc. 1 g/d vitamin C and 10 mg/d zinc for 94 participants. The combination
decreased the duration or rhinorrhoea
Masek 1974 Low dose. Two large studies of Czech coal miners comparing 0.1 g/d vitamin C and placebo over a period of
4 or 8 weeks. Excluded both on the basis of low dose and inadequacy of data for inclusion in meta-analyses.
The trials were neither randomised nor blind. Authors claimed benefits to the active recipients
Niemi 1951 Low dose and no placebo comparison. Finnish study with military recruits. 1036 people were observed during
a 3-month period. 516 were administered 0.1 g/d vitamin C. No benefits of vitamin C
Peters 1940 No placebo comparison. Short-term baby supplementation study
Schmidt 2011 Vitamin C in combination with vitamin D, folic acid and selenium. Double-blind, placebo-controlled RCT
with 192 patients with recurrent colds. Authors claimed benefits to the active recipients
g/d: grams per day
RCT: randomised controlled trial
RR: risk ratio
SD: standard deviation
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D A T A A N D A N A L Y S E S
Comparison 1. Incidence of colds while taking ≥ 0.2 g/day vitamin C regularly




participants Statistical method Effect size
1 Proportion of participants
developing ≥ 1 cold episodes
during the trial
29 11306 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.92, 0.98]
1.1 All eligible trials with
exception of subgroup removed
below
24 10708 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.94, 1.00]
1.2 Short-term exposure to
severe physical stress and/or
cold
5 598 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.35, 0.64]
Comparison 2. Duration of the colds occurring when on regular ≥ 0.2 g/day vitamin C




participants Statistical method Effect size
1 Duration of common cold
symptoms (placebo group
duration 100%)
31 9745 Mean Difference (IV, Fixed, 95% CI) -9.38 [-12.86, -5.90]
1.1 Trials with adults 17 7215 Mean Difference (IV, Fixed, 95% CI) -7.72 [-11.76, -3.69]
1.2 Trials with children 14 2530 Mean Difference (IV, Fixed, 95% CI) -14.19 [-21.07, -7.
31]
Comparison 3. Severity of the colds occurring when on regular ≥ 0.2 g/day vitamin C




participants Statistical method Effect size
1 Indicators of common cold
severity
16 7209 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.17, -0.07]
1.1 Mean days indoors or off
work or school
7 5066 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.17, -0.05]
1.2 Mean symptom severity
score
9 2143 Std. Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.22, -0.05]
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Comparison 4. Duration of the colds after therapeutic ≥ 0.2 g/day vitamin C




participants Statistical method Effect size
1 Duration of common cold
symptoms (placebo group
duration 100%)
7 3249 Mean Difference (IV, Fixed, 95% CI) -2.90 [-8.20, 2.39]
Comparison 5. Severity of the colds after therapeutic ≥ 0.2 g/day vitamin C




participants Statistical method Effect size
1 Indicators of common cold
severity
4 2708 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.15, 0.01]
1.1 Mean days indoors or off
work or school
3 2569 Std. Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.16, -8.25]
1.2 Mean symptom severity
score
1 139 Std. Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.21, 0.51]
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Analysis 1.1. Comparison 1 Incidence of colds while taking ≥ 0.2 g/day vitamin C regularly, Outcome 1
Proportion of participants developing ≥ 1 cold episodes during the trial.
Review: Vitamin C for preventing and treating the common cold
Comparison: 1 Incidence of colds while taking ≥ 0.2 g/day vitamin C regularly
Outcome: 1 Proportion of participants developing ≥ 1 cold episodes during the trial
Study or subgroup Vitamin C Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All eligible trials with exception of subgroup removed below
Peters 1996b 5/41 11/45 0.4 % 0.50 [ 0.19, 1.31 ]
Moolla 1996b 5/11 12/19 0.3 % 0.72 [ 0.35, 1.50 ]
Charleston 1972 31/47 37/43 1.5 % 0.77 [ 0.60, 0.97 ]
Coulehan 1974a 19/190 23/192 0.9 % 0.83 [ 0.47, 1.48 ]
Anderson 1972 302/407 335/411 12.7 % 0.91 [ 0.85, 0.98 ]
Coulehan 1974b 16/131 17/128 0.7 % 0.92 [ 0.49, 1.74 ]
Dahlberg 1944 131/1259 142/1266 5.4 % 0.93 [ 0.74, 1.16 ]
Bancalari 1984 21/32 21/30 0.8 % 0.94 [ 0.67, 1.32 ]
Anderson 1974a 922/1191 233/285 14.4 % 0.95 [ 0.89, 1.01 ]
Franz 1956 14/44 15/45 0.6 % 0.95 [ 0.52, 1.74 ]
Sasazuki 2006 68/140 67/133 2.6 % 0.96 [ 0.76, 1.23 ]
Cowan 1942 184/208 142/155 6.2 % 0.97 [ 0.90, 1.03 ]
Ludvigsson 1977b 230/304 240/311 9.1 % 0.98 [ 0.90, 1.07 ]
Pitt 1979 298/331 309/343 11.6 % 1.00 [ 0.95, 1.05 ]
Coulehan 1976 98/428 98/428 3.7 % 1.00 [ 0.78, 1.28 ]
Clegg 1975 48/67 50/70 1.9 % 1.00 [ 0.81, 1.24 ]
Elwood 1976 296/339 298/349 11.2 % 1.02 [ 0.96, 1.09 ]
Briggs 1984 125/265 121/263 4.6 % 1.03 [ 0.85, 1.23 ]
Carson 1975 85/121 84/123 3.2 % 1.03 [ 0.87, 1.22 ]
Van Straten 2002 35/84 34/84 1.3 % 1.03 [ 0.72, 1.48 ]
Ludvigsson 1977a 49/80 44/78 1.7 % 1.09 [ 0.84, 1.41 ]
Liljefors 1972 10/33 9/33 0.3 % 1.11 [ 0.52, 2.38 ]
Peters 1993b 18/34 18/39 0.6 % 1.15 [ 0.72, 1.82 ]
Himmelstein 1998a 10/23 8/25 0.3 % 1.36 [ 0.65, 2.84 ]
0.5 0.7 1 1.5 2
Favours vitamin C Favours placebo
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(. . . Continued)
Study or subgroup Vitamin C Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 5810 4898 96.1 % 0.97 [ 0.94, 1.00 ]
Total events: 3020 (Vitamin C), 2368 (Placebo)
Heterogeneity: Chi2 = 17.75, df = 23 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Short-term exposure to severe physical stress and/or cold
Peters 1996a 7/44 19/47 0.7 % 0.39 [ 0.18, 0.84 ]
Sabiston 1974 6/56 14/56 0.5 % 0.43 [ 0.18, 1.04 ]
Moolla 1996a 4/13 13/19 0.4 % 0.45 [ 0.19, 1.07 ]
Peters 1993a 14/43 28/41 1.1 % 0.48 [ 0.30, 0.77 ]
Ritzel 1961 17/139 31/140 1.2 % 0.55 [ 0.32, 0.95 ]
Subtotal (95% CI) 295 303 3.9 % 0.48 [ 0.35, 0.64 ]
Total events: 48 (Vitamin C), 105 (Placebo)
Heterogeneity: Chi2 = 0.60, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 4.99 (P < 0.00001)
Total (95% CI) 6105 5201 100.0 % 0.95 [ 0.92, 0.98 ]
Total events: 3068 (Vitamin C), 2473 (Placebo)
Heterogeneity: Chi2 = 44.85, df = 28 (P = 0.02); I2 =38%
Test for overall effect: Z = 3.18 (P = 0.0015)
Test for subgroup differences: Chi2 = 22.74, df = 1 (P = 0.00), I2 =96%
0.5 0.7 1 1.5 2
Favours vitamin C Favours placebo
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Analysis 2.1. Comparison 2 Duration of the colds occurring when on regular ≥ 0.2 g/day vitamin C,
Outcome 1 Duration of common cold symptoms (placebo group duration 100%).
Review: Vitamin C for preventing and treating the common cold
Comparison: 2 Duration of the colds occurring when on regular ≥ 0.2 g/day vitamin C
Outcome: 1 Duration of common cold symptoms (placebo group duration 100%)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Trials with adults
Van Straten 2002 37 58 (96) 50 100 (150) 0.5 % -42.00 [ -93.82, 9.82 ]
Himmelstein 1998a 14 60 (26) 12 100 (82) 0.5 % -40.00 [ -88.35, 8.35 ]
Carr 1981b 57 65 (75) 71 100 (75) 1.8 % -35.00 [ -61.14, -8.86 ]
Sabiston 1974 6 72 (50) 14 100 (50) 0.5 % -28.00 [ -75.82, 19.82 ]
Peters 1993b 18 75 (38) 18 100 (56) 1.2 % -25.00 [ -56.26, 6.26 ]
Charleston 1972 44 84 (46) 80 100 (20) 5.9 % -16.00 [ -30.28, -1.72 ]
Peters 1996a 7 85 (85) 19 100 (100) 0.2 % -15.00 [ -92.37, 62.37 ]
Karlowski 1975a 128 87.4 (51.5) 65 100 (52) 5.1 % -12.60 [ -28.07, 2.87 ]
Anderson 1974a 1823 93 (102) 437 100 (99) 11.2 % -7.00 [ -17.40, 3.40 ]
Briggs 1984 125 94 (94) 121 100 (100) 2.1 % -6.00 [ -30.27, 18.27 ]
Elwood 1976 627 94 (90) 690 100 (99) 11.6 % -6.00 [ -16.21, 4.21 ]
Anderson 1972 561 95 (92) 609 100 (82) 12.1 % -5.00 [ -15.02, 5.02 ]
Clegg 1975 68 95 (41) 73 100 (39) 6.9 % -5.00 [ -18.23, 8.23 ]
Pitt 1979 600 97.4 (100) 619 100 (100) 9.6 % -2.60 [ -13.83, 8.63 ]
Carr 1981a 94 101 (96) 70 100 (96) 1.4 % 1.00 [ -28.70, 30.70 ]
Peters 1993a 14 103 (17) 28 100 (42) 3.8 % 3.00 [ -14.93, 20.93 ]
Peters 1996b 5 136 (136) 11 100 (100) 0.1 % 36.00 [ -97.05, 169.05 ]
Subtotal (95% CI) 4228 2987 74.4 % -7.72 [ -11.76, -3.69 ]
Heterogeneity: Chi2 = 14.66, df = 16 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
2 Trials with children
Constantini 2011a 30 53 (48) 21 100 (68) 1.1 % -47.00 [ -80.78, -13.22 ]
Ludvigsson 1977a 62 61 (41) 55 100 (67) 2.9 % -39.00 [ -59.44, -18.56 ]
Ritzel 1961 17 69 (51) 31 100 (51) 1.3 % -31.00 [ -61.17, -0.83 ]
Coulehan 1974b 16 71 (71) 17 100 (100) 0.3 % -29.00 [ -87.91, 29.91 ]
-20 -10 0 10 20
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bancalari 1984 38 76 (62) 46 100 (65) 1.6 % -24.00 [ -51.23, 3.23 ]
Wilson 1973a 160 84.5 (131) 126 100 (134) 1.3 % -15.50 [ -46.48, 15.48 ]
Miller 1977c 116 87 (73) 122 100 (73) 3.5 % -13.00 [ -31.55, 5.55 ]
Coulehan 1974a 19 88 (88) 23 100 (100) 0.4 % -12.00 [ -68.88, 44.88 ]
Miller 1977a 53 93 (105) 42 100 (105) 0.7 % -7.00 [ -49.51, 35.51 ]
Ludvigsson 1977b 423 94 (85) 398 100 (114) 6.3 % -6.00 [ -19.82, 7.82 ]
Coulehan 1976 98 95 (95) 98 100 (100) 1.6 % -5.00 [ -32.31, 22.31 ]
Miller 1977b 42 97 (50) 40 100 (50) 2.6 % -3.00 [ -24.65, 18.65 ]
Wilson 1973b 205 108 (150) 187 100 (132) 1.6 % 8.00 [ -19.92, 35.92 ]
Constantini 2011b 23 116 (74) 22 100 (111) 0.4 % 16.00 [ -39.37, 71.37 ]
Subtotal (95% CI) 1302 1228 25.6 % -14.19 [ -21.07, -7.31 ]
Heterogeneity: Chi2 = 17.74, df = 13 (P = 0.17); I2 =27%
Test for overall effect: Z = 4.04 (P = 0.000053)
Total (95% CI) 5530 4215 100.0 % -9.38 [ -12.86, -5.90 ]
Heterogeneity: Chi2 = 34.92, df = 30 (P = 0.25); I2 =14%
Test for overall effect: Z = 5.28 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.53, df = 1 (P = 0.11), I2 =60%
-20 -10 0 10 20
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Analysis 3.1. Comparison 3 Severity of the colds occurring when on regular ≥ 0.2 g/day vitamin C,
Outcome 1 Indicators of common cold severity.
Review: Vitamin C for preventing and treating the common cold
Comparison: 3 Severity of the colds occurring when on regular ≥ 0.2 g/day vitamin C
Outcome: 1 Indicators of common cold severity







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean days indoors or off work or school
Sabiston 1974 6 0.8 (0.8) 14 2.4 (2.1) 0.2 % -0.84 [ -1.83, 0.16 ]
Ludvigsson 1977a 62 0.95 (1.12) 55 1.9 (2.42) 1.8 % -0.51 [ -0.88, -0.14 ]
Wilson 1973a 160 4.52 (6.32) 126 5.94 (6.28) 4.4 % -0.22 [ -0.46, 0.01 ]
Ludvigsson 1977b 423 1.47 (1.27) 398 1.81 (1.79) 12.9 % -0.22 [ -0.36, -0.08 ]
Anderson 1972 561 1.04 (1.75) 609 1.32 (2) 18.5 % -0.15 [ -0.26, -0.03 ]
Anderson 1974a 1823 1.14 (1.71) 437 1.15 (1.52) 22.4 % -0.01 [ -0.11, 0.10 ]
Wilson 1973b 205 4.2 (4.44) 187 3.84 (4.51) 6.2 % 0.08 [ -0.12, 0.28 ]
Subtotal (95% CI) 3240 1826 66.5 % -0.11 [ -0.17, -0.05 ]
Heterogeneity: Chi2 = 17.73, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 3.58 (P = 0.00035)
2 Mean symptom severity score
Constantini 2011a 30 26 (30) 21 66 (85) 0.7 % -0.67 [ -1.24, -0.09 ]
Himmelstein 1998a 14 16.1 (14.59) 12 37.4 (52.65) 0.4 % -0.55 [ -1.34, 0.23 ]
Carr 1981b 57 21.9 (33.57) 71 33.6 (33.57) 2.0 % -0.35 [ -0.70, 0.00 ]
Miller 1977c 116 14.6 (20) 122 19 (20) 3.8 % -0.22 [ -0.47, 0.04 ]
Pitt 1979 600 1.87 (0.76) 619 1.97 (0.76) 19.3 % -0.13 [ -0.24, -0.02 ]
Miller 1977a 53 22.5 (45.5) 42 27.3 (45.5) 1.5 % -0.10 [ -0.51, 0.30 ]
Carr 1981a 94 23.6 (33.57) 70 22.2 (33.57) 2.5 % 0.04 [ -0.27, 0.35 ]
Constantini 2011b 51 25 (64) 89 22 (52) 2.1 % 0.05 [ -0.29, 0.40 ]
Miller 1977b 42 48.6 (22.6) 40 46.2 (22.6) 1.3 % 0.11 [ -0.33, 0.54 ]
Subtotal (95% CI) 1057 1086 33.5 % -0.14 [ -0.22, -0.05 ]
Heterogeneity: Chi2 = 9.80, df = 8 (P = 0.28); I2 =18%
Test for overall effect: Z = 3.13 (P = 0.0018)
Total (95% CI) 4297 2912 100.0 % -0.12 [ -0.17, -0.07 ]
Heterogeneity: Chi2 = 27.76, df = 15 (P = 0.02); I2 =46%
Test for overall effect: Z = 4.72 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 4.1. Comparison 4 Duration of the colds after therapeutic ≥ 0.2 g/day vitamin C, Outcome 1
Duration of common cold symptoms (placebo group duration 100%).
Review: Vitamin C for preventing and treating the common cold
Comparison: 4 Duration of the colds after therapeutic ≥ 0.2 g/day vitamin C
Outcome: 1 Duration of common cold symptoms (placebo group duration 100%)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Anderson 1974e 900 85 (91) 437 100 (99) 23.0 % -15.00 [ -26.02, -3.98 ]
Karlowski 1975c 56 90 (41) 65 100 (52) 10.2 % -10.00 [ -26.59, 6.59 ]
Anderson 1975a 419 97 (96) 213 100 (84) 13.2 % -3.00 [ -17.55, 11.55 ]
Elwood 1977 145 99 (75) 119 100 (51) 12.0 % -1.00 [ -16.26, 14.26 ]
Tyrrell 1977 274 103 (57) 329 100 (54) 35.2 % 3.00 [ -5.92, 11.92 ]
Cowan 1950 77 110 (100) 76 100 (100) 2.8 % 10.00 [ -21.69, 41.69 ]
Audera 2001a 97 121 (80) 42 100 (76) 3.6 % 21.00 [ -6.96, 48.96 ]
Total (95% CI) 1968 1281 100.0 % -2.90 [ -8.20, 2.39 ]
Heterogeneity: Chi2 = 10.52, df = 6 (P = 0.10); I2 =43%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours vitamin C Favours placebo
87Vitamin C for preventing and treating the common cold (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.1. Comparison 5 Severity of the colds after therapeutic ≥ 0.2 g/day vitamin C, Outcome 1
Indicators of common cold severity.
Review: Vitamin C for preventing and treating the common cold
Comparison: 5 Severity of the colds after therapeutic ≥ 0.2 g/day vitamin C
Outcome: 1 Indicators of common cold severity







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean days indoors or off work or school
Anderson 1975a 416 0.86 (1.1) 213 1.1 (1.46) 22.9 % -0.19 [ -0.36, -0.03 ]
Anderson 1974e 900 1.07 (1.54) 437 1.17 (1.52) 48.0 % -0.07 [ -0.18, 0.05 ]
Tyrrell 1977 274 0.33 (0.83) 329 0.34 (1.21) 24.4 % -0.01 [ -0.17, 0.15 ]
Subtotal (95% CI) 1590 979 95.2 % -0.08 [ -0.16, 0.00 ]
Heterogeneity: Chi2 = 2.64, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 1.98 (P = 0.048)
2 Mean symptom severity score
Audera 2001a 97 34.83 (41.77) 42 29 (30.67) 4.8 % 0.15 [ -0.21, 0.51 ]
Subtotal (95% CI) 97 42 4.8 % 0.15 [ -0.21, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 1687 1021 100.0 % -0.07 [ -0.15, 0.01 ]
Heterogeneity: Chi2 = 4.13, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.76 (P = 0.079)
Test for subgroup differences: Chi2 = 1.49, df = 1 (P = 0.22), I2 =33%
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A D D I T I O N A L T A B L E S
Table 1. Included trials with no data suitable for our meta-analysis
Trial Findings
Abbott 1968 Therapeutic trial. The authors write: “with regard to the comparative results with the two preparations, there were
virtually no differences at all in respect of any of these individual symptoms” [p 444]. The only numerical data
reported were the severity of “sore throat in patients with a common cold” [their Table 1 on p 443]. It is not clear
how long a delay there was between the onset of symptoms and the initiation of treatment. “The doctors taking
part in the trial were asked to treat families in order, as colds appeared during the course of the winter” [p 442];
thus it seems that the doctor gave tablets only when he or she met the patient rather than patient keeping tablets
ready at home for use when symptoms started
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Table 1. Included trials with no data suitable for our meta-analysis (Continued)
Asfora 1977 Therapeutic trial. The author writes: “a double-blind trial was conducted in which the preparations, numbered 1
and 8, were given to alternate patients as they presented themselves. .. When 42 patients had received substance
No. 1 and 41 patients had received No. 8, there was no longer any point in continuing the double-blind trial, since
in view of the clinical progress of the patients there was not the slightest doubt that substance No. 1 was vitamin
C and No. 8 was the placebo” [p 224]. Thereafter the trial was continued as an open trial comparing vitamin C
with other drugs
Brown 1945 Therapeutic trial. Of the 206 “nasal colds”, 62% (76/123) of the vitamin C group had a cold being cured overnight
whereas 37% (31/83) of the placebo participants had colds that were cured overnight (P = 0.06). There was
no difference in the curing of 92 “throat colds” (35/56 versus 22/36, respectively). The great difference in the
distribution of participants is not consistent with reported alternate allocation
Elliot 1973 Prophylactic trial. The authors write: “There was no consistent difference between groups in the incidence of runny
nose or sneezing. Man-days of morbidity for hoarseness, sore throats, non-productive coughs, and productive
coughs was 36, 107, 42 and 72 in the placebo group with only 37%, 28%, 40% and 31% as much morbidity in
the ascorbic acid group. The Wilcoxon Sequence Test with a one tailed test rejected the null hypothesis of equal
effectiveness of ascorbic acid and placebo for sore throats and productive coughs (P = .0155 and .0327) but not
for hoarseness or non-productive coughs” [p 12] (Hemilä 2004).
Regnier 1968 Therapeutic trial. The author writes: “I initiated a double-blind study using ascorbic acid alone, ascorbic acid
plus bioflavonoids, flavonoids only and, fourthly, a lactose placebo with the two ”vitamins“ present either alone or
together in 200 mg quantities. It was shortly obvious that there was no need to continue double-blind techniques.
The continued studies were done by the single blind method... ”
“The 22 subjects mentioned have been studied systematically and under conditions which were as controlled as
is possible in a clinical investigation of an infection such as the common cold. Some acted as what are commonly
termed their own controls... None of the subjects was studied for less than three years... [p 950].” “Within the first
24 hours of a typical infection which the patient recognizes as his usual early symptoms of a cold, and the sooner
the better, the beginning dose of ascorbic acid or 0.6 or 0.625 g is taken every three hours” (p 950). The author
reports that “in 50 colds the treatment consisted of ascorbic acid alone ... the colds were nicely suppressed in 45
[of the 50]... In 22 of 24 instances in which the lactose-filled capsules alone were taken the colds were seemingly
untempered and ordinary” [p 952]
Scheunert 1949 Prophylactic trial. The common cold [Erkältungskrankheiten] was one of the outcomes and “The percentage
monthly duration of people sick with the common cold [Prozentualer Monatsdurchschnitt der erkrankten Perso-
nen]” was 7.3% in the 0.02 g/d group, 7.2% in the 0.05 g/d group, 1.95% in the 0.1 g/d group, and 1.93% in the
0.3 g/d group suggesting that there were more days sick with the common cold when vitamin C doses were low.
However, the data are presented ambiguously and it is a combination of incidence and duration. The methodology
is not good
Tebrock 1956 Therapeutic trial. The authors conclude “the overwhelming impression gained from the study is the singular lack
of effect in altering the course of the common cold by ... the ascorbic acid”. A number of tables were published
but they could not be used in our meta-analyses
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Table 2. Three trials with experimentally induced colds
Study characteristics Walker 1967 Schwartz 1973 Dick 1990
Number of participants 91 healthy volunteers; 47 vitamin
C and 44 placebo
21 healthy male volunteers Altogether 48 participants. Three
separate transmission experiments
each involving 16 healthy volun-
teers (8 vitamin C; 8 placebo)
housed closely for 1 week with 8
volunteers actively infected with
rhinovirus
Viruses used Rhinovirus (3 strains); 29 vitamin
C and 26 placebo
Influenza B (8/8)
B814 virus (10/10)
Rhinovirus 44; 11 vitamin C and
10 placebo
Rhinovirus 16; 24 vitamin C and
24 placebo
Transmission method Nasal instillation Nasal instillation Close contact with infected volun-
teers over a period of a week
Intervention 1 g/d vitamin C for 3 days before
and 6 days after inoculation
3 g/d vitamin C or placebo for 2
weeks before and 1 week after in-
oculation
2 g/d vitamin C for 3.5 weeks be-
fore exposure to infected volun-
teers
Incidence outcome 18 colds developed in each group All in both groups developed colds 19/24 in vitamin C group and 22/
24 in placebo group became in-
fected
Duration outcome Mean duration in each group 5
days
Both groups resolved by 6 to 7
days
Not provided
Severity outcome Mean severity score 8 for vitamin
C and 7 for placebo
Severity peaked earlier for vitamin
C group and resolution more ad-
vanced by day 4 (P = 0.02). Over-
all mean severity scores not signif-
icantly different in the 2 groups
Mean cumulative severity score
and mucus weights reduced in the
vitamin C recipients (P = 0.03).
Severity of colds reduced by 50%
(P = 0.02; Dick 1990)
Comments Not double-blind Double-blind. Nasal virus shed-
ding similar in the 2 groups
Dou-
ble-blind. Viral shedding similar
in these 2 groups. The studies are
briefly described in a series of con-
ference abstracts but no full pub-
lished paper is available
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A P P E N D I C E S
Appendix 1. History and search strategies prior to 2012
In the first 1998 edition of this Cochrane Review (Douglas 1998), an analysis was made of the 30 published trials that had been selected
by two previous systematic reviewers, Hemilä 1992 and Kleijnen 1989. That selection of trials was one of convenience and was justified
by the fact that all had been carried out post-Pauling in an era of relatively sophisticated trial methodology, and mainly using doses of
vitamin C at the level recommended by Pauling (i.e. 1 g per day or more).
For the 2004 revised edition of this Cochrane Review (Douglas 2004), all known publications on the topic in the past 64 years were
included. Some of these trials had been carried out since the original 1998 review, but also the controlled trials published before 1970
(pre-Pauling period) were added. We set the limit of daily vitamin C administration to 0.2 g/day, so that controlled trials with lower
doses were not included in the review, but were listed and commented on in the excluded studies table.
Twenty-five additional trials were then added to the review, including a number of trials which evaluated the utility of vitamin C in
the prevention of post-race colds among marathon runners and further explored the role of vitamin C as a therapy for colds.
For the 2004 update, we again searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (The Cochrane Library Issue 2, 2004); MEDLINE (January 1966 to June 2004) and EMBASE (1990 to June Week 23 2004).
For the 2004 update, we also screened the reference lists incorporated in a series of systematic reviews of the literature published by
Briggs 1984 and Kleijnen 1989 (for the search strategy of the latter, see Kleijnen 1992) and the references in those studies. One of
the review authors (HH) has a research involvement spanning over a decade in this topic and has assembled a large personal reference
list of papers published in the grey literature or listed in indexing services that preceded electronic searching. These were added to a
primary database which was then systematically screened by two review authors (BD and Ron D’Souza - a previous review author)
who worked together to exclude duplicate entries, preliminary reports of data more fully reported elsewhere, commentaries, editorials
and other papers which did not contain unique reports of controlled or randomised clinical comparisons. These two review authors
then separately reviewed hard copies or electronic abstract data on each of 84 papers, applying the selection criteria outlined above. A
final list of 62 papers was selected, which contained unique data from one or more trials of vitamin C and the common cold. One of
the papers (Bibile 1966 cited by Kleijnen 1989) remains unassessed as we have been unable to retrieve a copy through library orders.
Twenty-six of the 61 remaining papers failed to meet the selection criteria.
This left us with 36 papers, of which 12 contained reports of two or more (up to six) unique study comparisons and an entry for each
comparison was made into the ’Characteristics of included studies’ table, using the letters a, b, c, d, e and f to identify different study
comparisons within the one publication. The review in 2004 included data from 56 distinct trial comparisons, which was 25 more
than in the original 1998 review. In four of the papers (Anderson 1974a; Anderson 1975a; Audera 2001a; Karlowski 1975a) more
than one actively treated group was compared with the same placebo-treated group. To avoid the ’unit of analysis problem’ for which
we were legitimately criticised in the original 1998 review, where multiple active arms were considered separately in the same meta-
analysis, they were combined as one entry.
For the 2007 update (Douglas 2007), we searched CENTRAL (The Cochrane Library Issue 4, 2006), MEDLINE (2004 to December
2006) and EMBASE (1990 to December 2006). In the 2007 update, only one new trial was identified (Sasazuki 2006).
The 2007 MEDLINE search









10 5 and 9
For the 2010 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, issue
1), which contains the Acute Respiratory Infections Group’s Specialised Register, MEDLINE (2006 to February 2010) and EMBASE
(2006 to February 2010).
See below the search strategy for MEDLINE. The EMBASE and CENTRAL searches were slightly modified to fit the databases (see
Appendix 2 for EMBASE search strategy).
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MEDLINE (OVID)





6 exp Ascorbic Acid/
7 ascorb$.mp.
8 (vitamin$ adj5 C).mp.
9 or/6-8
10 5 and 9
EMBASE search run from 01 January 2006 to 03 February 2010
10. #5 AND #9
9. #6 OR #7 OR #8
8. ascorb*:ab,ti
7. (vitamin* NEAR/5 c):ab,ti
6. ’ascorbic acid’/exp
5. #1 OR #2 OR #3 OR #4
4. rhinovir*:ab,ti
3. ’human rhinovirus’/exp OR ’rhinovirus infection’/exp OR ’rhinovirus’/de
2. ’common cold’:ab,ti OR ’common colds’:ab,ti
1. ’common cold’/de OR ’common cold symptom’/de
There were no language or publication restrictions in the literature searches.
Appendix 2. Embase.com search strategy 2012
#11 #7 AND #10 361
#10 #8 OR #9 58878
#9 (vitamin* NEAR/5 c):ab,ti OR ascorb*:ab,ti 39136
#8 ’ascorbic acid’/exp 50266
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6 8168
#6 ((viral OR virus*) NEAR/2 rhinit*):ab,ti 84
#5 ’acute rhinitis’:ab,ti 85
#4 rhinovir*:ab,ti 3158
#3 ’human rhinovirus’/de OR ’rhinovirus infection’/de 1204
#2 ’common cold’:ab,ti OR ’common colds’:ab,ti OR coryza:ab,ti 2466
#1 ’common cold’/de OR ’common cold symptom’/de 4344
Appendix 3. CINAHL (EBSCOhost) search strategy 2012
S13 S7 and S11 16
S12 S7 and S11 91
S11 S8 or S9 or S10 3342
S10 TI vitamin* N5 c OR AB vitamin* N5 c 1762
S9 TI ascorb* OR AB ascorb* 586
S8 (MH “Ascorbic Acid”) 2325
S7 S1 or S2 or S3 or S4 or S5 or S6 1767
S6 TI ((viral or virus*) N2 rhinit*) OR AB ((viral or virus*) N2 rhinit* ) 5
S5 TI acute rhinitis OR AB acute rhinitis 30
S4 TI coryza OR AB coryza 23
S3 TI rhinovirus* OR AB rhinovirus* 153
S2 TI common cold* OR AB common cold* 501
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S1 (MH “Common Cold”) 1400
Appendix 4. LILACS (BIREME) search strategy 2012
VHL > Search > (MH:“Common Cold” OR “Resfriado Común” OR “Resfriado Comum” OR “Coriza Aguda” OR catarro OR coryza
OR rhinovir$ OR MH:rhinovirus OR “acute rhinitis” OR “viral rhinitis”) AND (MH:“ascorbic acid” OR “Ácido Ascórbico” OR
“Vitamin C” OR MH:D02.241.081.844.107$ OR MH:D02.241.511.902.107$ OR D09.811.100$ OR “Vitamina C”)
Appendix 5. Web of Science (Thomson Reuters) search strategy 2012
Topic=(“common cold” or “common colds” or rhinovir* or coryza or “acute rhinitis” or “viral rhinitis” or (virus* NEAR/2 rhinitis))
AND Topic=(“ascorbic acid” or ascorb* or (vitamin* NEAR/5 c)) Refined by: Publication Years=( 2011 OR 2010 OR 2012 )
Timespan=1955-2012. Databases=SCI-EXPANDED, CPCI-S, CCR-EXPANDED, IC.
Lemmatization=On
Appendix 6. Trials Registers search strategy 2012
common cold AND vitamin c
ascorbic acid AND common cold
F E E D B A C K
Flaws in statistical analysis?
Summary
There appear to be several instances where there is considerable overlap between studies, but they are treated as independent studies
as far as the meta-analysis is concerned. For example, the Anderson 1974, 1974a, 1974b studies seem to be treated as independent in
graph (comparison 01, outcome 04), but the control groups seem identical, and 275 people in the treatment group seem the same in
each study. The effect is to inflate the value of this study. Indeed, the difference between the treatment groups for Anderson 1974a,
1974b (33 new people, *all* apparently with one or more respiratory episodes) raises further issues.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
In the new edition of the review we have avoided this problem described above by combining all trial arms that were compared with
the one placebo group into one trial arm for purposes of the meta-analysis
Reply supplied by the authors of the review.
Contributors
David Wooff
Comment and reply posted 28 August 2004
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Unit of analysis issues
Summary
Further to David Wooff ’s comment, I suspect there may be other statistical flaws in this review that could be placed under the heading,
’unit of analysis errors’.
At least one study (Lugviggson) appears to be a cluster randomised trial, yet there is no discussion of the possible over-weighting of this
study when naively included in the meta-analyses.
At least two studies appear to be twin studies (Carr and Miller). Should the matching be taken into account in the analysis, in a similar
way to a simple cross-over trial?
The particular meta-analysis for ’Mean symptom days per person’ in the comparison ’Vitamin C 1G daily or more vs placebo’ worries
me considerably. Of the six studies (10 contributions) included in this analysis, I suspect that at most two are free of unit of analysis
errors of various kinds. This makes it a wonderful teaching example, but for the wrong reasons.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
Ludvigsson writes explicitly “Every class was divided at random into two groups.” In our opinion this statement means that Ludvigsson
was taking one class and he divided the participants of that one class into to two groups ’at random,’ and then he went to another class
and similarly randomised the second class. We disagree that cluster randomisation applied here.
As to the two small twin trials: Miller 1977 explicitly stated that “analysis of the paired comparisons…” so we conclude their SE values
in their main table are based on paired t-test, event though this is not explicitly stated in their methods; Carr 1981 explicitly stated
“the results for the six summary cold variables of the paired analyses of variance between active and placebo groups are shown…” so we
conclude their P-values refer to paired analyses. In any case, the mean difference between the groups is the same whether we calculate
difference of means or mean of paired differences. Failure to take into account the pairing of data would mean that we would be over-
conservative in our estimate of the precision of any effect, but it is unlikely that this issue would anyway have influenced our conclusions
in a meaningful way.
In the current review we have not used as an outcome variable mean symptom days per person but have concentrated on mean symptom
days per episode.
Reply supplied by the Authors of the review.
Contributors
Julian Higgins
Comment and reply posted 28 August 2004
Doses too small
Summary
One gram daily is a small dose. Most mammals make 3 or more grams in their livers. Any practitioner of orthomolecular medicine
knows that a minimum of several grams a day is needed to surely prevent a cold, and as much as 20 grams to cure one in progress. Not
one trial in your RCT’s qualifies.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms
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Reply
The practitioners of orthomolecular medicine have not to our knowledge published any controlled trial evidence on which this comment
is based. As we have said in the review, there is no reasonable doubt that vitamin C supplementation plays some biological role in
defence, and there is tantalising evidence from the Anderson 1974 study that a single therapeutic dose of 8 grams at commencement
of a cold may have had a useful therapeutic effect.
We believe there is a case for rigorous evaluation of the possibility that very large doses (of the order of 8 g daily in adults for periods
up to five days after the onset of symptoms) could produce benefits that were not seen at lower doses.
In view of the greater propensity of children to catch colds and the greater benefits observed in the child prophylaxis studies, this may
be the group in which to explore this approach (with an appropriately pro-rated dose for weight). We add however a caution. Although
studies in which doses of 1 or 2 g daily of vitamin C have been used for several months have not produced convincing evidence of
adverse effects to the volunteers, dosage of the kind discussed here needs to be carefully monitored for adverse effects - especially in
children.
Reply supplied by the Authors of the review.
Contributors
Reuven Gilmore
Comment and reply posted 28 August 2004
Vitamin C for preventing and treating the colds
Summary
This paper by Hemila and Douglas is highly misleading. Two fundamental scientific errors invalidate the conclusions of their review.
Their first error is the dose range: the doses employed are too small. Treatment of disease requires pharmacological doses of vitamin C,
in the range 10 to 200 g per day [Cathcart, Medical Hypotheses, 7, 1359-76]. Prevention of disease requires a minimum of 2.5 g per
day, in divided doses, to establish a dynamic flow through the body. In defending their review, Hemila and Douglas cite Levine [Levine
et al. JAMA, 1999, 281,1415-23] as showing that the body is saturated by a dose of 0.5 g per day: this finding has been discredited.
A more recent paper by Levine and colleagues shows that the body is not saturated by doses up to 18 g per day. [Padayatty et al, Ann
Intern Med, 2004, 140, 533-7]. This discrepancy has been explained in a recent book [Hickey and Roberts, Ascorbate, 2004, Lulu
press].
The second error concerns the dose frequency. Since high doses of vitamin C have a half-life of about 30 minutes, single or twice daily
doses do not increase plasma levels for more than a few hours [Levine et al. JAMA 1999, 281,1415-23]. Such doses provide a minimal
protective effect. Given these infrequent doses, even a small positive effect implies a powerful therapeutic potential.
Douglas and Hemila have not shown that vitamin C is ineffective against the common cold, unless the doses used are both inadequate
and inappropriate. They have, however, made clear that the previous 65 years of research has been based on a range of doses that are too
small and too infrequent. Thus, the research to date may grossly underestimate the therapeutic value of vitamin C. Tests of appropriate
dose levels and timing regimes are urgently required.
Reply
Hickey and Roberts claim that the prophylactic and therapeutic trials that have been carried out to date have used a range of doses that
are too small and too infrequent. They speculate, on the basis of pharmacodynamic studies, that prevention of disease would require a
minimum of 2.5 g of vitamin C per day in divided doses. If they firmly believe in their reasoning (there are good grounds for debate),
they or someone else need to undertake rigorous prophylactic trials at such dosage levels.
Nevertheless, while stating that “prevention of disease requires a minimum of 2.5 g/day”, Hickey and Roberts ignore our finding that
in six trials with participants under heavy physical or cold stress or both, vitamin C halved the incidence of common cold type of
symptoms (our Fig 01). This benefit was seen with doses of 0.25 to 1.0 g/day which is substantially less than those speculated as
minimal by Hickey and Roberts. Thus in our Fig 01 the living conditions rather than the vitamin C dosage provided the explanation
to the heterogeneous trial results.
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Our review does not claim that the issue is closed. It acknowledges that vitamin C plays some biological role in defence against respiratory
infections but finds no evidence that at doses up to 1 to 2 g/day vitamin C would prevent colds in the general population or reduce
common cold duration enough to justify regular supplementation.
Finally, we drew attention to one study in which an 8 g therapeutic dose seemed to be beneficial and underlined the fact that no
therapeutic trials have been carried out in children even though the regular supplementation trials found greater effect in children.
Harri Hemilä and Robert M Douglas
Contributors
Steve Hickey PhD. Manchester Metropolitan University
Hilary Roberts PhD
Comment and reply posted 16 November 2005
Vitamin C doses in trial
Summary
Studies which find the effects of vitamin C on the common cold inconclusive invariably use less than 1 g of ascorbic acid a day.
Proponents of Vitamin C therapy consistently use 3 or more grams a day. This debate will not be resolved until both camps start testing
the same dosages. Since the ascorbic acid proponents acknowledge that < 1 g a day will have little therapeutic effect, it is incumbent on
researchers to analyze the effect of megadoses.
I routinely dose to bowel tolerance. 0.5 g every hour for eight hours will reach bowel tolerance for me. When I begin to become ill, I
have dosed as high as 0.5 g every 20 minutes without reaching bowel tolerance. I can significantly reduce the effect of a cold in this
fashion, and once was the only one functioning in my office when everyone else was sick.
My rule of thumb is 35 mg per pound of body weight per day. This must be distributed throughout the day to prevent overloading
the ability of the stomach to absorb it, and to provide continuous saturation, because of the rapid decomposition of ascorbic acid once
it is no longer in crystalline form. This dose is consistent with the levels of ascorbic acid produced by the liver of other mammals.
Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
Our review shows that the relation between vitamin C dosage and effect is not as simple as Sean Emerson suggests. We found statistically
significant heterogeneity in the effect of vitamin C on common cold incidence. The heterogeneity was not explained by vitamin C
dosage but by segregating trials with people under heavy acute physical stress to a separate group. In the latter subgroup, vitamin C
halved the common cold risk, yet the doses in the trials were rather low, from 0.25 to 1 g/day. Prophylactic trials with the general
population found no evidence that vitamin C would prevent colds, even though the highest prophylactic dose was 3 g/day (Karlowski
1975).
In the therapeutic trials, the dose-response is also complex. Several studies with 3 to 4 g/day failed to find therapeutic benefit (Cowan
1950, Elwood 1977, Tyrrell 1977, Audera 2001). Thus, the negative findings in therapeutic trials are not simply explained by the use
of ascorbic acid in “doses less than 1 gram a day”. On the other hand, Anderson 1975 found statistically significant 25% reduction in
“days spent indoors per subject” with dosage of 1 to 1.5 g/day for five days. This benefit is not explained by the use of particularly high
doses.
We pointed out that in the Karlowski 1975 trial 6 g/day was associated with a double benefit compared with 3 g/day. We also pointed
out that Anderson 1974 reported that 8 g/day on the first day of the common cold appeared better than 4 g/day. Thus, there are scattered
data suggesting dose dependency, but these findings are more relevant for planning further trials than for immediate conclusions to
claim dose-dependency.
Based on the trials analysed in our review, we do not consider that regular supplementation of the ordinary people is justified. On the
other hand, vitamin C is inexpensive and safe in doses of grams per day and, while waiting for new therapeutic trials, testing vitamin C
for common cold treatment may be reasonable at an individual level. However, explicit evidence from well-conducted trials is required
for broad recommendations to use vitamin C for treating the common cold, and such evidence is missing.
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Reply by Hemilä, Douglas, Chalker (22 August 2007)
Contributors
Sean Emerson
Comment posted 24 July 2007
Vitamin C and the common cold, 2 May 2008
Summary
Introduction
The Cochrane review provides a meta-analysis of low-dose studies of vitamin C and the common cold. Unfortunately, its authors limit
the range of intakes to values that are marginally effective, and exclude clinical data on higher doses, which have been shown to provide
positive results.
The review fails to understand orthomolecular claims for vitamin C in prevention and treatment of the common cold, repeated over a
period of at least 50 years.[i],[ii],[iii],[iv],[v],[vi] Orthomolecular nutrition and medicine are concerned with varying the concentrations
of substances such as vitamin C, which are normally present in the body, to prevent or control disease; typically, this involves large
doses of nutrients. The doses Douglas et al. refer to as “mega-dose vitamin C supplementation” range from 200 mg, once or twice daily.
These are small doses.
To avoid misunderstanding, we state the orthomolecular claims for vitamin C:
Vitamin C given at frequent intervals (< 6 hourly) and sufficiently high doses (8+ grams per day) will prevent common colds in the
majority of subjects (individual variation is high).
Vitamin C, given at short intervals and very high doses to a subject with the common cold, can eliminate the symptoms and may bring
about a cure within hours [1,2,3,3,5, 6,7]. Cathcart suggests 30-150 grams per day, at intervals of one hour or less.[vii] The Vitamin
C Foundation recommends 8 grams every 20 minutes, from the onset of symptoms.
The dose-response relationship for the treatment claim is described as a threshold effect; unless a minimum threshold dose is reached,
little or no clinical response is achieved.[viii]
Review shortcomings
Methodology
1. If a reviewer is aware of author names, experimental details, and results, she can influence the outcome of the review by unfair
selection; even honest experimenters are subject to unconscious effects. In this case, the reviewers had prior knowledge of the literature
on vitamin C and the common cold, and specific knowledge of the papers under consideration. The researchers were aware that selection
criteria would exclude ALL clinical reports of high (orthomolecular) doses. These problems have been communicated to the authors,
though their response has been unsatisfactory. A clear and objective response might provide reassurance that the potential for bias was
being addressed.
2. As described in another Cochrane review, the placebo effect is irrelevant in the case of definitive and objective clinical effects. The
effects claimed for vitamin C are large, objective, and definitive [6]. Orthomolecular physicians report complete, dose-related, reversal
of symptoms, or rapid cure. The review required placebo controls on the basis that the authors considered “that with the expected small
effects of vitamin C, and the greatly subjective outcome definitions, only placebo-controlled trials could yield information of adequate
rigour.” Such an expectation is based on a misconception of the claims for vitamin C. The explanation is particularly inadequate, as it
restricts the doses studied to outliers of the range claimed to be effective.
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Results
3. The review does not include data for intakes of the order of magnitude described in the orthomolecular prevention or treatment
claims. This objection was made by Hickey and Roberts, and Higgins, in response to an earlier version, later reinforced by Emerson.
Douglas et al. responded tangentially and failed to explain how their data could be extrapolated to cover the doses claimed to be effective.
4. The review covers longer dose intervals than those claimed to be effective. Hickey and Roberts published this objection and again
the response by Douglas and Hemilä did not indicate how their data could be extrapolated to more frequent doses.
5. The reviewers disregard the pharmacokinetics of vitamin C. The half-life for kidney excretion of high-dose vitamin C from plasma is
about 30 minutes [6]. At the dose levels and intervals studied by Douglas et al., there would be little, if any, consistent increase in plasma
ascorbate levels or body content. The action of vitamin C depends on its ability to donate and transfer electrons: if the ascorbate has
been excreted, it cannot exert this redox effect. A rigorous response is required, as this failure breaches basic principles of pharmacology.
Conclusions
6. The reviewers dismiss the observations of Cathcart and others, on the grounds that “their uncontrolled observations do not provide
valid evidence of benefit”. Scientifically, such experimental results are more valid than large-scale clinical trials or epidemiological
studies. The scientific method involves hypothesis and refutation.[i] Easily replicable experiments, as reported by internationally-known
physicians, such as Cathcart, Klenner, Hoffer, Levy, Kalokerinos, and Brighthope, have great scientific validity. If these observations
were in error then, over the last half century, any physician or scientist could have refuted the claims, with little effort or cost. No such
refutation exists in the literature.6
7. The authors failed to identify the limitations of their review. Their results relate to low doses: approximately an order of magnitude
less than those claimed to be effective. The review did not specify that its results and conclusions exclude orthomolecular and other
clinical claims for the effectiveness of vitamin C.
8. Taken as a whole, the review and resultant media generalisations are misleading, as they deflect attention away from the actual claims
for vitamin C’s effectiveness. The authors have promoted their conclusions widely under the Cochrane name, resulting in generalisations
that are out of proportion to a scientific interpretation of the data. A widely-quoted press release from Douglas’ university begins
“vitamin C has been proven ineffective in combating the common cold in most people.” Douglas claims, “vitamin C has proven not to
be a magic bullet to solve the common cold”.[i] We can find no evidence in the Cochrane review to support such unscientific claims,9
let alone provide anything close to “proof”.9 The hypothesis that appropriate doses of vitamin C can prevent or cure the common cold
has not been refuted and we ask that this review be withdrawn [6].
[1] Klenner F.R. (1953) The Use of Vitamin C as an Antibiotic, The Journal of Applied Nutrition, 6, 274-278.
[2] Stone I. (1972) Vitamin C Against Disease: The Healing Factor, Perigree Books.
[3] Cathcart R.F. (1981) The Method of Determining Proper Doses of Vitamin C for the Treatment of Disease by Titrating to Bowel
Tolerance, Orthomolecular Psychiatry, 10(2),125-132.
[4] Lewin S. (1976) Vitamin C: Its Molecular Biology and Medical Potential, Academic press.
[5] Levy T. (2002) Vitamin C, Infectious Diseases and Toxins, Xlibris Corp.
[6] Hickey S. Roberts H. (2004) Ascorbate: The Science of Vitamin C, Lulu press.
[7] Cathcart R. (1981) Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy, Medical Hypotheses, 7, 1359-
1376.
[8] Cathcart R.F. (1985) Vitamin C: the non-toxic,nonrate-limited, antioxidant free radical scavenger, Medical Hypotheses, 18, 61-77.
[9] Popper K. (1963) Conjectures and Refutations: The Growth of Scientific Knowledge. Routledge.
[10] Amanda Morgan (2005) News from The Australian National University, Tuesday 28 June.
Reply
Reply to Hickey and Roberts’ comments, May 2008
Hickey and Roberts reiterate comments to which we have already replied. See the earlier discussions. Here we focus on fundamental
issues related to the evaluation of medical interventions.
First, Hickey and Roberts criticise us for excluding uncontrolled observations from our systematic review. The importance of control
groups in the evaluation of medical interventions is discussed in basic textbooks of clinical trials and epidemiology and also in the
Cochrane Handbook (1). We do not repeat the arguments here. The Cochrane Collaboration focuses mainly on randomised controlled
trials, but non-randomised controlled studies can be included when justified; however, the inclusion of uncontrolled observations is
not an option (Ref. 1, Chapter 13). With their opinion that “uncontrolled observations are more valid than large-scale clinical trials
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or epidemiological studies”, Hickey and Roberts challenge the whole Cochrane Collaboration and not just our review on the common
cold.
Second, Hickey and Roberts state that “the placebo effect is irrelevant in the case of definitive and objective clinical effects.” Even
though the placebo effect has often been exaggerated, there is firm evidence of placebo effect on patient-reported continuous outcomes
and on pain measured as a continuous outcome (2). Moreover, in their meta-analysis examining the role of methodology in controlled
trials, Balk et al. (3) found that the lack of placebo control biased the treatment effects of paediatric trials that measured soft outcomes
of respiratory diseases. Therefore, the absence of placebo leads to a high risk of bias in trials on the common cold, which is a short-
lasting and non-severe disease with soft outcomes.
Third, Hickey and Roberts are not consistent in their argumentations. They state that “even honest experimenters are subject to
unconscious effects”, yet they ignore this wisdom when they lean on the uncontrolled observations by vitamin C enthusiasts.
Our review was largely motivated by the work of Linus Pauling, who hypothesised in the early 1970s that grams of vitamin C per day
would prevent colds. We found that trials in the general community do not support Pauling’s hypothesis, whereas trials with individuals
under heavy acute physical stress do. The statistically highly significant effect in the latter group of trials refutes Hickey and Roberts’
argument that our “results relate to low doses: approximately an order of magnitude less than those claimed to be effective.” The
heterogeneity we found indicates that the characteristics and conditions of people are important in determining the effect of vitamin
C, whereas we do not see basis to assume that doses that are an order of magnitude higher than those used in the prophylactic trials
(up to 3 grams per day) would prevent colds in the general community.
The purpose of our systematic review was not to test Hickey and Roberts’ orthomolecular claims and none of the identified controlled
trials directly test them. With their belief that frequent high-dose vitamin C supplementation prevents colds in all people, and their note
that testing vitamin C effects requires “little effort or cost”, Hickey and Roberts should consider organizing by themselves a randomised
controlled trial to examine their orthomolecular claims.
1 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008].
The Cochrane Collaboration, 2008. Available at: http://www.cochrane.org/resources/handbook/
2 Hrobjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004;(2): CD003974.
3 Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau J. Correlation of quality measures with estimates of
treatment effect in meta-analyses of randomised controlled trials. JAMA 2002; 287: 2973-82.
Contributors
Steve Hickey PhD and Hilary Roberts PhD
Feedback and reply added 13 June 2008
Vitamin C for preventing and treating the common cold, 25 November 2008
Summary
I would be interested in your results if you restricted studies to those using 1.0 grams or more.
Submitter agrees with default conflict of interest statement:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
We have previously replied to overlapping feedbacks on the dose-response issue (see the other comments). In this update, we calculated
the effect of 1 g/day or more on common cold incidence in the general community trials and also with this restriction there is strong
evidence that prophylactic vitamin C has no effect on the average incidence of colds. None of the five trials with physically stressed
people used over 1 g/day and therefore the benefit in that group is not explained by particularly high dosage.
We note that Karlowski 1975 and Coulehan 1974 used two different doses within the same trials and with the same outcome definitions.
Karlowski found that for adults, 6 g/day was associated with a double benefit compared with 3 g/day, and Coulehan found that for
school children, 2 g/day caused about twice the benefit of 1 g/day (Hemilä 1996a; Hemilä 1999a). Although these findings do not
establish dose dependency, they are interesting and support the case for examination of higher doses in therapeutic trials.
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Harri Hemila, Liz Chalker, Bob Douglas
Added 13 November 2009
Contributors
Roger Mann M.D.
W H A T ’ S N E W
Last assessed as up-to-date: 29 November 2012.
Date Event Description
29 November 2012 New citation required but conclusions have not
changed
Seven placebo-controlled trials, which were previously
excluded because there were no data suitable for our
meta-analyses, have been included (Table 1). Their
exclusion was inconsistent with the Methods section.
This change did not result in changes to our conclu-
sions (Abbott 1968; Asfora 1977; Briggs 1984; Elliot
1973; Regnier 1968; Scheunert 1949; Tebrock 1956)
.
In previous versions ’prophylactic’ was used to indi-
cate the trials in which vitamin C was administered
every day. ’Prophylactic’ is relevant when measuring
the incidence of episodes. However, that term is con-
fusing when measuring the duration of episodes that
occur during the trial. Therefore, in the 2012 version,
we changed to the term ’regular supplementation’ to
indicate trials in which vitamin C was administered
every day
29 November 2012 New search has been performed Searches conducted. We included one new trial (
Constantini 2011a; Constantini 2011b) and excluded
two new trials (Maggini 2012; Schmidt 2011).
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 1, 1998
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Date Event Description
2 February 2010 New search has been performed No new trials identified in this updated search. How-
ever, one trial with marathon runners was excluded
because of the high level of drop-outs and severe
bias in the drop-out rate between the study arms
(Himmelstein 1998b). We excluded the Audera 2001c
trial arm because flavonoids were administered in ad-
dition to vitamin C. We restricted the review to purely
vitamin C comparisons. The conclusions remain un-
changed since the last update (Douglas 2007).
13 November 2009 Feedback has been incorporated Feedback comment and reply added.
13 June 2008 Feedback has been incorporated Feedback comment and reply added.
12 June 2008 Amended Converted to new review format.
23 July 2007 Feedback has been incorporated Feedback added.
15 November 2005 Feedback has been incorporated Feedback added.
27 August 2004 Feedback has been incorporated Feedback comment added.
11 June 2004 New citation required and conclusions have changed Substantive amendment.
C O N T R I B U T I O N S O F A U T H O R S
Harri Hemilä (HH) carefully reviewed drafts of the second edition of the review (Douglas 2004), assisted in paper retrieval, proposed
alterations to data presentation, checked data entries and contributed significant input to the text. After the 2004 revision, he took
over responsibility for future updates of this review.
Elizabeth Chalker (EC) wrote the protocol for the first edition of the review (Douglas 1998), developed the initial search strategy,
undertook the searches, organised retrieval of papers, screened papers against inclusion criteria and appraised the quality of papers for
the 1998 version. She has been involved in reviewing and rewriting the text for subsequent versions of this review.
D E C L A R A T I O N S O F I N T E R E S T
None of the other review authors have any conflict of interest to declare in this review.
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S O U R C E S O F S U P P O R T
Internal sources
• Australian National University (until 2004), Australia.
External sources
• Commonwealth Department of Health and Ageing, Australia.
N O T E S
Full-text versions of references which are available either free or at the publishers’ databases can be accessed via the home page of the
contact author, Harri Hemilä: www.mv.helsinki.fi/home/hemila/CC/.
Seven placebo-controlled trials which were previously excluded because there were no data suitable for our meta-analyses have been
included (Table 1). Their exclusion was inconsistent with the Methods section. Their inclusion did not result in changes to our
conclusions.
In previous versions “prophylactic” was used to indicate the trials in which vitamin C was administered every day. “Prophylactic” is
relevant when measuring the incidence of episodes. However, that term is confusing when measuring the duration of episodes that
occur during the trial. Therefore, in the 2012 version, we changed to the term “regular supplementation” to indicate trials in which
vitamin C was administered every day.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Oral; Ascorbic Acid [administration & dosage; ∗therapeutic use]; Common Cold [∗drug therapy; ∗prevention &
control]; Randomized Controlled Trials as Topic; Respiratory Tract Infections [drug therapy; prevention & control]
MeSH check words
Humans
102Vitamin C for preventing and treating the common cold (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
